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ANTI-COCAINE COMPOSITIONS AND 
TREATMENT 
2 
Kuhar M. J (1999) J Med Chern 42, 2721-2736). The two 
types of therapies that are available for the treatment of opioid 
abuse, antagonism (e.g., naltrexone) and replacement (e.g., 
methadone), do not have parallels in the case of cocaine, CROSS-REFERENCE TO RELATED 
APPLICATIONS 5 although attempts at the latter are being considered (e.g., J. 
The present application is a continuation of U.S. Nonpro-
visional Application Ser. No. 12/373,510, filed 10 Jul. 2007 
issued as U.S. Pat. No. 8,318,158 on 27 Nov. 2012; which 
claims the benefit of priority to International PatentApplica- 10 
tionNo. PCTIUS07/15762, filed 10 Jul. 2007, and U.S. Pro-
visional Application No. 60/819,569, filed 10 Jul. 2006; each 
of which is incorporated herein by reference in its entirety. 
Grabowski eta!. (2004)Addictive Behaviors 29, 1439-1464). 
One approach is to prevent or reduce the cocaine from reach-
ing sites of action by administering either endogenous 
esterases, cocaine specific antibodies, or a catalytic antibody. 
Naturally occurring cocaine is hydrolyzed at the benzoyl 
ester by serum butyrylcholinesterase (BChE) to nontoxic 
ecgonine methyl ester and benzoic acid. In the liver, carboxy-
lesterase hCE-2 hydrolyzes the methyl ester to yield ben-
zoylecgonine and methanol (see e.g., FIG. 1). The elimina-
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
15 tion half-life of cocaine in the blood ranges from 0.5 to 1.5 hr 
(T. Inaba (1989) Canadian Journal of Physiology & Pharma-
cology 67, 1154-1157). There have been a few attempts to use 
naturally occurring BChE or genetically engineered BChE to This invention was made with government support under 
Grant DA021416 and Grant DA013683 awarded by National 
Institute of Health. The government has certain rights in the 20 
invention. 
INCORPORATION-BY-REFERENCE OF 
MATERIAL SUBMITTED ON A COMPACT DISC 
increase cocaine breakdown (see e.g., Carmona eta!. (2000) 
Drug Metabolism & Disposition 28, 367-371; Xie et a!. 
(1999) Molecular Pharmacology 55, 83-91; Sun eta!. (2002a) 
Molecular Pharmacology; Sun et a!. (2002b) Pharmacology 
& Experimental Therapeutics 302, 710-716; Duysen eta!. 
(2002) Journal of Pharmacology & Experimental Therapeu-
The Sequence Listing, which is a part of the present dis-
closure, includes a computer readable form and a written 
sequence listing comprising nucleotide and/or amino acid 
sequences of the present invention. The sequence listing 
information recorded in computer readable form is identical 
to the written sequence listing. The subject matter of the 
Sequence Listing is incorporated herein by reference in its 
entirety. 
25 tics 302, 751-758; Gao Y and Brimijoin S (2004) Journal of 
Pharmacology & Experimental Therapeutics 310, 1046-
1052; Gao eta!. (2005) Molecular Pharmacology 67, 204-
211). Other researchers have utilized a monoclonal antibody, 
Mab 15A10, as a catalytic antibody to cocaine (see e.g., 
30 Landry et a!, 1993; Mets et a!., 1998; Baird et a!., 2000; 
Larsen et a!., 2004), while others are exploring the use of 
cocaine vaccines (see e.g., Kosten et a!. (2002) Vaccine 20, 
1196-1204). 
FIELD OF THE INVENTION 
The invention disclosed herein generally relates to anti-
cocaine therapeutics. 
BACKGROUND 
35 
40 
45 
Abuse of cocaine is an intractable social and medical prob-
lem that is resistant to remediation through pharmacotherapy. 
Cocaine acts to block the reuptake of monoamines, dopam-
ine, norepinephrine, and serotin thus prolonging and magni-
fying the effects of these neurotransmitters in the central 
nervous system (Benowitz N L (1993) Pharmacal Toxicol 72, 
3-12). Cocaine toxicity is marked by both convulsions and 
cardiac dysfunction (e.g., myocardial infarction, cardiac 
arrhythmias, increased blood pressure, stroke, or dissecting 50 
aneurysm, and increased myocardial oxygen demand), due to 
effects on neurotransmitter systems and myocardial sodium 
channel blockade (Bauman J Land DiDomenico R J (2002) J 
Cardiovasc Pharmacal Ther 7, 195-202; Wilson L D and 
ShelatC (2003) JToxicol Clin Toxicol41, 777-788; Knuepfer 55 
M M (2003) Pharmacal Ther 97, 181-222). Because of 
cocaine's ability to readily cross the blood brain barrier and 
its widespread effects on the central and peripheral nervous 
systems, overdose can result in sudden death (see Bauman J L 
and DiDomenico R J (2002) J Cardiovasc Pharmacal Ther 7, 60 
195-202, for review). 
Although the mechanism of cocaine's action is well under-
stood, this information has not yet resulted in the develop-
ment of an effective antagonist of cocaine that could be used 
in abuse and overdose situations. The rapid and pleiotropic 65 
effects of cocaine present a complex problem for the treat-
ment of acute cocaine toxicity (Carroll F I, Howell L L and 
TABLE 1 
Kinetics of several cocaine hydrolyzing 
enzymes against (-) cocaine. 
Kcat Krn Efficiency 
Enzyme (min-1) (f!M) (kcat/Krn) Reference 
BChE 4.1 4.5 9.1 X 106 Sun et al., 2002a 
Ala328W/Y332A 154 18 8.5 X 106 Sun et al., 2002a 
Mab15A10 2.2 220 1 X 104 Larsen et al., 2004 
AME359 620 20 3.1 X 107 Gao et al., 2005 
CocE 468 0.64 7.2 X 108 Turner et al., 2002 
A bacterium, Rhodococcus sp. MB 1, indigenous to the soil 
surrounding the coca plant, has evolved the capacity to utilize 
cocaine as its sole carbon and nitrogen source. The bacterium 
expresses a cocaine esterase (CocE) that acts similarly to 
BChE to hydrolyze the benzoyl ester of cocaine, yielding 
ecgonine methyl ester and benzoic acid (see e.g., FIG. 1) 
(Bresler et a!. (2000) Appl Environ Microbial 66, 904-908; 
Turneretat. (2002) Biochemistry 41, 12297-12307; Larsenet 
a!. (2002) Nature Struct Biol9, 17-21). The gene forCocEhas 
been isolated and cloned (Bresler eta!. (2000) Appl Environ 
Microbiol66, 904-908), and the crystal structure ofCocE has 
been determined (Turner et at. (2002) Biochemistry 41, 
12297-12307; Larsen et a!. (2002) Nature Struct Bioi 9, 
17-21). The structure of CocE (see e.g., FIG. 2) reveals a 
classic serine esterase fold in addition to two other domains 
that combine to form a cocaine binding pocket. Altering any 
of three amino acids (Asp, His, or Ser) within the catalytic 
triad in the active site (for review, see Dodson G and 
Wlodawer A (1998) Trends Biochem Sci 23, 347-352) inac-
tivates the esterase activity against cocaine. Furthermore, 
mutation of residues that make contact with the benzoate 
US 9,200,265 B2 
3 
moiety of cocaine (e.g., Tyr44) also disrupts cocaine hydroly-
sis, presumably through impairing oxyanion stabilization in 
the transition state (Turner et a!. (2002) Biochemistry 41, 
12297-12307; Larsen eta!. (2002) Nature Structural Biology 
4 
CocE polypeptide within the scope of the invention and a 
pharmaceutically acceptable carrier or excipient. 
Another aspect of the invention provides isolated nucleic 
acids encoding the mutant CocE polypeptide described 
herein. In various embodiments, the nucleic acids include 
those with sequences that hybridize to the nucleic acid encod-
ing wild-type CocE (e.g., SEQ ID NO: 2), or the complement 
thereto, under high stringency conditions. Such isolated 
nucleic acid encodes a mutant CocE polypeptide having 
esterase activity with increased thermostability at 37° C. as 
compared to wild-type CocE. Various embodiments of the 
isolated nucleic acid sequence have at least about 85% 
sequence identity with the nucleic acid sequence of wild-type 
CocE (e.g., SEQ ID NO: 2). For example, the isolated nucleic 
acid sequence has at least about 86%, 87%, 88%, 89%, 90%, 
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% 
sequence identity of wild-type CocE (e.g., SEQ ID NO: 2). 
In various embodiments, mutant CocE polypeptides (or 
polypeptides encoded by nucleic acids within the scope of the 
9, 17-21). The purified enzyme (MW -65 kDa) catalyzes 5 
cocaine very efficiently with Michaelis-Menten kinetics 
kcaz=7 .2 s- 1 and Km=640 nM (Turner eta!. (2002) Biochem-
istry 41, 12297-12307; Larsen eta!. (2002) Nature Structural 
Biology 9, 17-21), nearly three orders of magnitude greater 
than endogenous esterases and, most likely, would act quickly 10 
enough to detoxifY humans who have overdosed on cocaine 
(Landry eta!. (1993) Science 259, 1899-1901; Mets eta!. 
(1998) National Academy of Sciences of the United States of 
America 95, 10176-10181). Additionally, the esterase also 15 
metabolizes cocaethylene, a potent metabolite of cocaine and 
alcohol, almost as efficiently as it metabolizes cocaine 
(kcat=9.4 s- 1 and Km=1600 nM) (Turner eta!. (2002) Bio-
chemistry 41, 12297-12307; Larsen et a!. (2002) Nature 
Structural Biology 9, 17-21). 20 invention) have increased melting temperatures as compared 
to wild-type CocE. In various embodiments, mutant CocE 
polypeptides (or polypeptides encoded by nucleic acids 
within the scope of the invention) increase mutant CocE 
polypeptide thermostability over wild-type CocE by at least 
Thus, it would be desirable to provide a stable CocE for 
anti-cocaine therapeutics. 
SUMMARY OF THE INVENTION 
Accordingly, the present inventors have succeeded in dis-
covering highly efficient, thermostable, and long-lasting 
cocaine esterase mutants that can protect against the toxic and 
reinforcing effects of cocaine in subjects. 
One aspect of the invention provides isolated mutant 
cocaine esterase (CocE) polypeptides of the wild-type CocE 
amino acid sequence (e.g., SEQ ID NO: 1) but with at least 
one amino acid residue substituted. The mutant CocE 
polypeptides have esterase activity with increased thermosta-
bility at 37° C. as compared to wild-type CocE. 
Various embodiments include mutant CocE polypeptides 
with at least two, three, four, five, or more substitutions of the 
wild-type CocE amino acid sequence. Examples of mutant 
CocE polypeptides within the scope of the invention include 
those with an amino acid sequence of SEQ ID NO: 3 
(L163V); SEQ ID NO: 7 (V225I); SEQ ID NO: 8 (I218L); 
SEQ ID NO: 9 (A310D); SEQ ID NO: 10 (A149S); SEQ ID 
NO: 11 (S159A); SEQ ID NO: 12 (S265A); SEQ ID NO: 13 
(S56G); SEQ ID NO: 14 (W220A); SEQ ID NO: 16 (S140A); 
SEQ ID NO: 17 (F189L); SEQ ID NO: 18 (A193D); SEQ ID 
NO: 19 (T254R); SEQ ID NO: 20 (N42V); SEQ ID NO: 21 
(V262L); SEQ ID NO: 22 (L508G); SEQ ID NO: 23 
(Y152H); SEQ ID NO: 24 (V160A); SEQ ID NO: 25 
(T172R); SEQ ID NO: 26 (Y532F); SEQ ID NO: 27 (T74S); 
SEQ ID NO: 28 (W285T); SEQ ID NO: 29 (L146P); SEQ ID 
NO: 30 (D533S); SEQ ID NO: 31 (A194R); SEQ ID NO: 32 
(G173Q); SEQ ID NO: 33 (C477T); SEQ ID NO: 34 
(K531A); SEQ ID NO: 35 (R41I); SEQ ID NO: 36 (L119A); 
SEQ ID NO: 37 (K46A); SEQ ID NO: 38 (F84Y), T172R-
G173Q (SEQ ID NO: 39); L169K (SEQ ID NO: 40); F189A 
(SEQ ID NO: 41 ), N197K (SEQ ID NO: 42), R182K (SEQ ID 
NO: 43), F 189K (SEQ ID NO: 44 ), V190K (SEQ ID NO: 45), 
Q191K (SEQ ID NO: 46), andA194K (SEQ ID NO: 47), or 
25 about 2.0 kcal/mol. For example, the increased thermo stabil-
ity can be at least about 2.1 kcal/mol, at least about 2.2 
kcal/mol, at least about 2.3 kcal/mol, at least about 2.4 kcal/ 
mol, at least about 2.5 kcal/mol, at least about 2.6 kcal/mol, at 
least about 2.7 kcal/mol, at least about 2.8 kcal/mol, at least 
30 about 2.9 kcal/mol, at least about 3.0 kcal/mol, at least about 
3.1 kcal/mol, at least about 3.2 kcal/mol, at least about 3.3 
kcal/mol, at least about 3.4 kcal/mol, at least about 3.5 kcal/ 
mol, at least about 3.6 kcal/mol, at least about 3.7 kcal/mol, at 
least about 3.8 kcal/mol, at least about 3.9 kcal/mol, at least 
35 about 4.0 kcal/mol, at least about 4.1 kcal/mol, at least about 
4.2 kcal/mol, at least about 4.3 kcal/mol, at least about 4.4 
kcal/mol, or at least about 4.5 kcal/mol. 
In various embodiments, mutant CocE polypeptides (or 
polypeptides encoded by nucleic acids within the scope of the 
40 invention) have reduced immunogenicity as compared to 
wild-type CocE. 
In some embodiments, the thermostable mutant CocE 
polypeptides have less esterase activity than wild-type CocE. 
For example, thermostable CocE mutants can have about 
45 10%, about 20%, about 30%, about 40%, about 50%, about 
60%, about 65%, about 70%, about 75%, about 80%, about 
85%, about 90%, about 95%, or about 99% of the esterase 
activity of wild -type CocE. In other embodiments, the mutant 
CocE polypeptides have approximately the same, or greater, 
50 catalytic efficiency of wild-type CocE polypeptides. For 
example, thermostable CocE mutants can have about 100%, 
about 110%, about 120%, about 130%, about 140%, about 
150%, or more of the esterase activity of wild-type CocE. 
In various embodiments, the mutant CocE polypeptides are 
55 pegylated. In various embodiments, the mutant CocE 
polypeptide is encapsulated in a red blood cell. For example, 
a pegylatedmutant CocE polypeptide(s) (or a pharmaceutical 
compos1t10n including a pegylated mutant CocE 
polypeptide(s)) can be encapsulated in a RBC. 
In some embodiments, the mutant CocE polypeptides are 
stabilized by a substrate, product, and/or inhibitor. 
a functional fragment(s) thereof. Additional exemplary 
mutant CocE polypeptides include, F189A/T172R, T172R/ 60 
A193D, T172R/G 173Q-117 5-G-G-A186, T172R/G 173Q-
T176-G-G-D185, and the like. Given the naming conventions 
and polypeptide sequences disclosed herein, one skilled in the 
Another aspect of the invention provides for methods of 
treating a cocaine-induced condition. In such methods, a 
therapeutically effective amount of a mutant CocE polypep-
65 tide(s) (or a pharmaceutical composition including a mutant 
CocE polypeptide(s)) within the scope of the invention is 
administered to a subject in need thereof. In various embodi-
art could determine the polypeptide sequences for the above-
named mutant CocE polypeptides. 
Another aspect of the invention provides pharmaceutical 
compositions that include among their components a mutant 
US 9,200,265 B2 
5 
ments, the cocaine-induced condition includes cocaine over-
dose, cocaine toxicity, cocaine addiction, cocaine depen-
dence, and/or some combination thereof. 
Yet another aspect of the invention provides for a high 
throughput screening method for identification of thermo- 5 
stable mutant CocE polypeptides. In such screening method, 
a cell is stably transformed with a nucleic acid encoding a 
mutant CocE polypeptide candidate. The mutant CocE 
polypeptide is expressed in the cell. The expressed mutant 
CocE polypeptide is isolated or displayed. The esterase activ- 10 
ity of the isolated mutant CocE polypeptide is measured at 
one or more temperatures to determine thermo stability of the 
isolated mutant CocE polypeptides. Such temperature(s) can 
be from about 30° C. to about 50° C. Mutant CocE polypep-
tide with esterase activity at the predetermined 15 
temperature( s) are selected. 
6 
the S159A mutant CocE (SEQ ID NO: 11) for reactions 
carried out at 30° C. and 37° C. For further methodology 
information, see Example 4. 
FIG. 6 is a set of photographs of the total protein staining 
after PAGE separation of wild-type and T172R mutant CocE 
using denaturing (SDS+~Me) or non-denaturing (Native) 
conditions after incubation at 37 C for various time points. 
For more information see Example 4. 
FIG. 7 is a line plot depicting the circular dichroism deter-
mined melting temperatures of wild-type and T172R CocE. 
The full spectrum is shown in A, the near-UV spectrum is 
shown in B, and the estimated melting temperature for each 
mutant is shown in C. For more information see Example 4. 
FIG. 8 contains (A) a drawing of the hydrolysis of the 
benzoylthioester derivative of cocaine (thio-1) and the des-
carbomethoxy cocaine (thio-2) followed by reaction of the 
released thiols (R-SH) with Ellman's reagent; and (B) a line 
plot showing the colorimetric reaction of control BL21 cells 
and BL21 cells containing CocE incubated with the ben-
zoylthioester derivative (thio-1) and Ellman's reagent. For 
more information see Example 15. 
FIG. 9 is a line and scatter showing the effect of 1.0 mg 
CocE (closed circles) or PBS (vehicle, open circles) on 
In some embodiments of the screening method, measuring 
esterase activity of the isolated mutant polypeptides can be 
accomplished by contacting the isolated mutant CocE 
polypeptide with (i) cocaine and a pH indicator or (ii) a 20 
thio-derivative of cocaine and a thiol indicator. Any change in 
the pH indicator or the thiol indicator is then detected. Such a 
change is correlated with the formation of benzoic acid from 
the hydrolysis of cocaine or cocaine derivative by the mutant 
CocE polypeptide. 25 cocaine-induced lethality when administered one minute 
after increasing doses of cocaine (n=6-7). Data presented are 
expressed as percent and its standard error. For further meth-
odology information, see Example 5. 
Some embodiments of the screening method further 
include conducting several cycles of the screening procedure 
at increasing temperatures for measuring esterase activity. 
For example, the first cycle can employ a temperature for 
measuring esterase activity of about 30° C. while a subse- 30 
quent cycle can employ a temperature for measuring esterase 
activity of about 45° C. 
In some embodiments of the screening method, expression 
of mutant CocE polypeptide occurs at a temperature at which 
wild type CocE substantially retains catalytic activity. In 35 
other embodiments of the screening method, expression of 
mutant CocE polypeptide occurs at a temperature at which 
wild-type CocE polypeptide substantially partitions into 
inclusion bodies. For example, the expression temperature 
can be at least about 35° C., at least about 36° C., at least about 40 
37° C., at least about 38° C., at least about 39° C., or at least 
about 40° C. 
Other objects and features will be in part apparent and in 
part pointed out hereinafter. 
BRIEF DESCRIPTION OF THE DRAWINGS 
45 
Those of skill in the art will understand that the drawings, 
described below, are for illustrative purposes only. The draw-
ings are not intended to limit the scope of the present teach- 50 
ings in any way. 
FIG. 10 is a bar graph showing the effect of increasing 
doses of CocE (CE) or human BChE (BChE), or PBS, on 
cocaine-induced lethality when administered one minute 
before 180 mg/kg cocaine (n=6-7). Data presented are 
expressed as percent and its standard error mean. For further 
methodology information, see Example 5. 
FIG. 11 is a bar graph showing the effect ofCocE mutants 
S 11 7 A andY 44 F, or PMSF treated CocE on cocaine-induced 
convulsions and lethality when administered 1 minute before 
180 mg/kg cocaine (n=5-6). For further methodology infor-
mation, see Example 5. 
FIG.12 is a bar graph showing the effect of 1.0 mg CocE or 
PBS administered one minute after the 560 mg/kg WIN-
35065-2, the determined LD100 of the compound (n=6-8). 
For further methodology information, see Example 5. 
FIG. 13 is a line and scatter plot showing time-dependent 
inactivation of CocE (125 ng/ml) in vitro. Exponential decay 
t112 was calculated as 13.2. For further methodology informa-
tion, see Example 6. 
FIG. 14 is a bar graph showing time-dependent protective 
effects of 1 mg CocE when administered at various times 
before and after 100 mg/kg cocaine (n=6-8) For further meth-
odology information, see Example 6. FIG. 1 is a diagram illustrating the metabolism of cocaine 
by various enzymatic reactions. 
FIG. 2 is a ribbon diagram illustrating the CocE structure. 
Domain 1 (DOM1), domain2 (DOM2), anddomain3 (DOM 
3) are indicated, along with the active site located at the 
intersection of the three domains. A benzoic acid molecule is 
shown in the active site. 
FIG. 15 is a bar graph showing the cocaine concentrations 
in human plasma treated with 0.8 f.LM cocaine esterase or 
55 esterase vehicle at zero and one minute following esterase 
administration. For further methodology information, see 
Example 6. 
FIG. 3 is a line plot depicting the elution profile for CocE 
by FPLC (Q-Sepharose ), where UV absorbance and sodium 
chloride concentration is shown over time. For further meth-
odology information, see Example 1. 
FIG. 4 is a line and scatter plot showing the in vitro degra-
dation of cocaine in the presence of CocE in human plasma. 
For further methodology information, see Example 2. 
FIG. 5 is Michaelis-Menten enzyme kinetics plot for wild-
type CocE, the T172R mutant CocE (SEQ ID NO: 26), and 
FIG. 16 is a series of line and scatter plots showing the 
effect of0.32 mg CocE (closed circles), 0.32 mg ofT172R 
60 mutant CocE (close triangles), or PBS (vehicle, open circles) 
on cocaine-induced lethality when administered one minute 
after increasing doses of cocaine (left panel) and minutes to 
death after cocaine administration (right panel). For further 
65 
methodology information, see Example 7. 
FIG.17 is a line and scatter plot showing the effect of0.32 
mg/kg of CocE (closed circles) or T172R mutant CocE 
(closed triangles) on cocaine-induced lethality when admin-
US 9,200,265 B2 
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istered at 1, 10, 30, and 60 minutes before administration of 
320 mg/kg cocaine (n=6). For further methodology informa-
tion, see Example 7. 
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FIG. 26 is a series of line and scatter plots demonstrating 
protective effects of CocE, T172R-G173Q, and their pegy-
lated forms against cocaine-induced toxicity. Each enzyme 
(0.3 mg) was administered intravenously 1 min before 
cocaine administration (mg/kg, i.p.). Different symbols rep-
resent dose-response curves of cocaine-induced lethality in 
the absence or presence of the enzyme. Each data point rep-
resents the percentage of mice (n=8 for each dosing condi-
tion) exhibiting cocaine-induced lethality. FIG. 26A depicts 
FIG. 18 is a series of line and scatter plots showing the 
effect of 1 mg of hBChE (closed triangle), 0.32 mg CocE 5 
(closed circle), or 1 mg of CocE (closed square) on cocaine-
induced lethality. FIG. 18A shows lethality as a function of 
cocaine concentration. FIG. 18B shows minutes until death 
after cocaine administration as a function of cocaine concen-
tration. For further methodology information, see Example 8. 10 the percentage occurrence oflethality as a function of cocaine 
dosage (mg/kg, i.p.) for Vehicle/PBS, CocE wild type (0.3. 
mg), and PEG-CocE wild type (0.3 mg). FIG. 26B depicts the 
percentage occurrence of lethality as a function of cocaine 
dosage (mg/kg, i.p.) for Vehicle/PBS, T172R-G173Q (0.3. 
FIG. 19 is a trace of the MALDI-TOF mass spectrum of 
pegylated CocE. Mass difference between peaks corresponds 
to -5500 Da; equivalent to the molecular weight of a single 
PEG chain. For further methodology information, see 
Example 11. 
15 mg), and PEG-Tl72R-G173Q (0.3. mg). 
FIG. 20 is an SEM image of gluteraldehyde fixed red blood 
cells. FIG. 20A is normal RBC without treatment. FIG. 20B 
is osmotic ruptire-reseal RBC loaded with L-ASNase. FIG. 
20C is RBC loaded with LMWP-ASNase. For further meth- 20 
odology information, see Example 12. 
FIG. 27 is a series of line and scatter plots showing the 
thermal stability of cocaine esterase and mutants: (A) wild-
type CocE, (B) T172R, (C) T272R/G173Q and L169K. For 
further methodology information, see Example 17. 
FIG. 28 is a series of chromatograms showing enzymes 
preincubated at 37° C. for 0 minutes or 60 minutes and 
resolved by size exclusion chromatography (A) wild-type 
CocE, (B) T172R, (C) T172R/G 173Q. Molecular weight 
standards, BSA (66 Kda) and AD (150 Kda) are included inA. 
FIG. 21 is a scatter plot showing percent Asperaginase 
activity in blood as a function of time (days) for RBC/LMP-
ASNase or RBC ghost/ASNase. For further methodology 
information, see Example 12. 25 For further methodology information, see Example 18. 
FIG. 22 is a line plot showing survival of DBA/2 mice 
bearing L5178Y lymphoma cells. Enzyme or saline were 
given on day 5, at which time symptoms were present. For 
further methodology information, see Example 12. 
FIG. 29 is a series of smoothed CD spectra of wild-type 
CocE and four mutants showing temperature dependent melt-
ing observed between 200 and 250 nm. For further method-
ology information, see Example 19. 
FIG. 30 is a series of spectra for wild-type CocE and four 
mutants deconvoluted to 3 curves via the CCA algorithm 
suggesting that the melting of CocE is at least a two-step 
process moving from he original curve (curve 1) to an inter-
mediate unfolding step (curve 2) to a fully denatured protein 
FIG. 23 is a line and scatter plots demonstrating protective 30 
effects of CocE and its mutants against cocaine-induced tox-
icity. The figure depicts percentage of mice lethality exhibit-
ing cocaine-induced lethality as a function of injected cocaine 
concentration in mice adminstered wild type CocE (0.3 mg), 
T172R (0.3 mg), T172R-G173Q (0.3 mg), or L169K (1 mg). 
CocE or mutants (mg) was administered intravenously 1 
minute before cocaine administration (mg/kg, i.p.). Different 
symbols represent dose-response curves of cocaine-induced 
lethality in the absence or presence of CocE or mutants. Each 
data point represents the percentage of mice (n=8 for each 40 
dosing condition) exhibiting cocaine-induced lethality. 
35 (curve 3). For further methodology information, see Example 
19. 
FIG. 24 is a series of line and scatter plots demonstrating 
time course of protective effects of CocE against cocaine 
toxicity. CocE or mutants (0.1, 0.3, and 1 mg, i.v.) was admin-
istered at different time points before administration of i.p. 45 
cocaine 180 mg/kg. FIG. 24A depicts percentage of mice 
exhibiting cocaine-induced lethality as a function of time of 
administration of wild type CocE (0.1 mg), T172R (0.1 mg), 
L169K (0.1 mg), or T172R-G173Q (0.1 mg) before admin-
istrationofi.p. cocaine 180 mg/kg. FIG. 24B depicts percent- 50 
age of mice exhibiting cocaine-induced lethality as a function 
of time of administration of wild type CocE (0.3 mg), T172R 
(0.3 mg), L169K (0.3 mg), orT172R-G173Q (0.1 mg) before 
administration of i.p. cocaine 180 mg/kg. FIG. 24C depicts 
percentage of mice exhibiting cocaine-induced lethality as a 55 
function of time of administration of wild type CocE (1 mg), 
T172R (1 mg), L169K (1 mg), or T172R-G173Q (1 mg) 
before administration of i.p. cocaine 180 mg/kg. Each data 
point represents the percentage of mice (n=8 for each dosing 
condition) exhibiting cocaine-induced lethality. 60 
FIG. 25 is a line and scatter plot demonstrating estimated 
duration of protection for 50% lethality. The figure depicts the 
estimated duration (hours) of protection (50% lethality) of 
CocE mutants in mice as a function of dosage (mg, i.v.) of 
T172R-G173Q, L169K, T172R, and wild type CocE. The 65 
time required to reach 50% lethality was determined from 
FIG. 24. 
FIG. 31 is a series of line and scatter plots showing per-
centage contribution of each temperature in describing the 3 
deconvoluted CCA curves shown in FIG. 30. For further 
methodology information, see Example 19. 
FIG. 32 is a line and scatter plot showing melting and 
formation temperatures for (1) the initial spectra melts, (2) the 
formation and melt of the intermediate state, and (3) the 
accumulation of the fully melted protein. For further meth-
odology information, see Example 19. 
FIG. 33 is a picture of a gel showing that Cocaine (mM 
range prevented 37° C.-induced formation of high molecular 
weight CocE aggregates (0.1 mg/ml enzyme concentrations. 
For further methodology information, see Example 20. 
FIG. 34 is a line and scatter plot showing that Cocaine (uM 
quantities) stabilized 37° C.-induced activity loss. For further 
methodology information, see Example 20. 
FIG. 35 is a picture of a gel showing that Benzoic acid (mM 
range prevented 37° C.-induced formation of high molecular 
weight CocE aggregates (0.1 mg/ml enzyme concentrations. 
For further methodology information, see Example 20. 
FIG. 36 is a line and scatter plot showing that Cocaine (uM 
quantities) stabilized 37° C.-induced activity loss. For further 
methodology information, see Example 20. 
DETAILED DESCRIPTION OF THE INVENTION 
Embodiments of the invention disclosed wherein provide 
compositions and methods for a catalytic degradation 
approach to anti-cocaine therapeutics. The technology 
described herein is based in part on the discovery of highly 
efficient, thermostable, and long-lasting cocaine esterase 
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mutants that can protect against the toxic and reinforcing 
effects of cocaine in subjects. Such mutants provide treatment 
options for cocaine-induced conditions such as cocaine over-
dose and cocaine addiction. 
Mutant CocE Polypeptides 
Despite the potency of wild-type CocE (see e.g., SEQ ID 
NO: 1, Accession No. AF173165) in metabolizing cocaine 
(see e.g., Example 2; Example 4; Example 5), application of 
wild-type CocE as a therapeutic agent in the treatment of 
cocaine overdose may be limited because of its low thermal 
stability at the physiological temperature ( se e.g., Example 4; 
Example 6). Thermo-instability contributes to the short 
plasma half-life of wild-type CocE. Significant decay (>50%) 
of CocE activity was observed following incubation of the 
enzyme in plasma at 3 7° C., or after its intravenous adminis-
tration into a mouse. The t112 of CocE at 37° C. is approxi-
mately 15 minutes whereas at 4° C. the t 112 is greater than 6 
months. Preliminary studies in rats demonstrated a relatively 
short duration of anti-cocaine effect of little more than 30 
minutes for CocE. 
One aspect of the invention thus provides purified mutant 
CocE polypeptides that exhibit increased thermal stability 
and plasma half-life as compared to wild-type CocE. The 
mutant CocE polypeptides of the invention hold significant 
clinical value because of their capability to efficiently hydro-
lyze cocaine, while also exhibiting increased thermo stability 
and/or plasma half-life. 
The invention provides mutant CocE polypeptides in 
which at least one amino acid residue of the wild-type CocE 
is substituted, where the mutant CocE has increased thermo-
stability while retaining relatively high catalytic efficiency. In 
some embodiments, mutant CocE polypeptides substantially 
maintain the wild-type CocE polypeptide functional esterase 
activity (i.e., hydrolysis of cocaine). Mutant CocE polypep-
tides have a peptide sequence that differs from a native CocE 
polypeptide in one or more amino acids. The peptide 
sequence of such mutants can feature a substitution, deletion, 
or addition of one or more amino acids of a native CocE 
polypeptide. Amino acid insertions are preferably of about 1, 
2, 3, and 4 to 5 contiguous amino acids, and deletions are 
preferably of about 1, 2, 3, 4, 5, 6, 7, 8, and 9 to 10 contiguous 
amino acids. In various embodiments, the mutant CocE 
polypeptide can contain at least one, two, three, four, or more 
amino acid substitutions, deletions, or additions, where the 
resulting mutant CocE polypeptide has increased thermosta-
bility. 
The term amino acid, as used herein, is intended to include 
naturally occurring amino acids as well as non-naturally 
occurring amino acids, including amino acid analogs and 
derivatives. The latter includes molecules containing an 
amino acid moiety. One skilled in the art will recognize that 
reference herein to an amino acid includes, for example, 
naturally occurring proteogenic L-amina acids; D-amino 
acids; chemically modified amino acids such as amino acid 
analogs and derivatives; naturally occurring non-proteogenic 
amino acids, and chemically synthesized compounds having 
properties known in the art to be characteristic of amino acids. 
For all the amino acid sequences disclosed herein, it is under-
stood that equivalent nucleotides and amino acids can be 
substituted into the sequences without affecting the function 
of the sequences. Such substitution is within the ability of a 
person of ordinary skill in the art. 
The invention also provides purified mutant CocE 
polypeptides with the following substitutions: L163V (SEQ 
ID NO: 3); V121D (SEQ ID NO: 4); S167 A (SEQ ID NO: 5); 
Q123E (SEQIDNO: 6);V225I (SEQID NO: 7); I218L (SEQ 
ID NO: 8); A310D (SEQ ID NO: 9); A149S (SEQ ID NO: 
10 
10); S159A (SEQ ID NO: 11); S265A (SEQ ID NO: 12); 
S56G (SEQ ID NO: 13); W220A (SEQ ID NO: 14); T122A 
(SEQ ID NO: 15); S140A (SEQ ID NO: 16); F189L (SEQ ID 
NO: 17);A193D(SEQIDNO: 18);T254R(SEQIDNO: 19); 
5 N42V (SEQ ID NO: 20); V262L (SEQ ID NO: 21); L508G 
(SEQ ID NO: 22); Y152H (SEQ ID NO: 23); V160A (SEQ ID 
NO: 24); T172R (SEQ ID NO: 25); Y532F (SEQ ID NO: 26); 
T74S (SEQ ID NO: 27); W285T (SEQ ID NO: 28); L146P 
(SEQ ID NO: 29); D533S (SEQ ID NO: 30); A194R (SEQ ID 
10 NO: 31 ); G 173Q (SEQ ID NO: 32); C477T (SEQ ID NO: 33); 
K531A (SEQ ID NO: 34); R41I (SEQ ID NO: 35); L119A 
(SEQ ID NO: 36); K46A (SEQ ID NO: 37); F84Y(SEQ ID 
NO: 38), T172R-G173Q (SEQ ID NO: 39); L169K (SEQ ID 
NO: 40); F189A (SEQ ID NO: 41), N197K (SEQ ID NO: 42), 
15 R182K (SEQ ID NO: 43), F189K (SEQ ID NO: 44), V190K 
(SEQ ID NO: 45), Q191K (SEQ ID NO: 46), and A194K 
(SEQ ID NO: 47). For example, the T172R mutant CocE 
polypeptide (SEQ ID NO: 25) has increased thermo stability, 
increased Vmax and Km at 37° C., increased melting tem-
20 perature (Tm), increased plasma half-life, greater reductions 
in lethality due to cocaine toxicity, and longer lasting anti-
cocaine effects, as compared to wild-type CocE (see e.g., 
Example 4, Example 7). 
The resulting increase in thermostability of the mutant 
25 CocE polypeptide is at least about 2 kcal/mol. Thermostabil-
ity of a given polypeptide can be assessed by a variety of 
methods known to the art, including for example circular 
dichroism (CD) spectroscopy or differential scanning calo-
rimeter. For example, the resulting increase in thermo stability 
30 can be at least about 2.1, at least about 2.2, at least about 2.3, 
at least about 2.4, at least about 2.5, at least about 2.6, at least 
about 2.7, at least about 2.8, at least about 2.9, at least about 
3.0, at least about 3.1, at least about 3.2, at least about 3.3, at 
least about 3.4, at least about 3.5, at least about 3.6, at least 
35 about 3.7, at least about 3.8, at least about 3.9, at least about 
4.0, at least about 4.1, at least about 4.2, at least about 4.3, at 
least about 4.4, or at least about 4.5 kcal/mol. Even greater 
thermo stability increases are contemplated. It is thought that 
lowering the energy by about 2.1 to about 4.5 kcal/mol can 
40 extend the half-life time of the protein about 30 to about 1000 
fold longer at room temperature. 
Generally, the mutant CocE polypeptides have esterase 
activity with increased thermostability as compared to wild-
type CocE. In some embodiments, the thermostable mutant 
45 CocE polypeptides can have less esterase activity than wild-
type CocE. For example, thermostable CocE mutants can 
have about 10%, about 20%, about 30%, about 40%, about 
50%, about 60%, about 65%, about 70%, about 75%, about 
80%, about 85%, about 90%, about 95%, or about 99% of the 
50 esterase activity of wild-type CocE. In other embodiments, 
the mutant CocE polypeptides have approximately the same, 
or greater, catalytic efficiency of wild-type CocE polypep-
tides. For example, thermostable CocE mutants can have 
about 100%, about 110%, about 120%, about 130%, about 
55 140%, about 150%, or more of the esterase activity of wild-
type CocE. 
Variants of the mutant CocE polypeptides such as frag-
ments, analogs, and derivatives are also within the invention. 
CocE polypeptide fragments corresponding to one or more 
60 particular motifs and/or domains or to arbitrary sizes, for 
example, at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 
19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35, 
36,37,38,39,40,50, 75,100,125,150,200,250,300,400, 
500, 600, 700, 800, 900, 1000, 1100, 1150 and 1200 amino 
65 acids in length are intended to be within the scope of the 
invention disclosed herein. Isolated peptidyl portions of 
CocE polypeptides can be obtained by screening peptides 
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recombinantly produced from the corresponding fragment of 
the nucleic acid encoding such peptides. In addition, frag-
ments can be chemically synthesized using techniques known 
in the art such as conventional Merrifield solid phase f-Moe or 
t-Boc chemistry. For example, a CocE polypeptide as 
described herein can be arbitrarily divided into fragments of 
desired length with no overlap of the fragments, or preferably 
divided into overlapping fragments of a desired length. 
Another aspect of the invention disclosed herein concerns 
recombinant forms of the CocE polypeptide. In some 
embodiments, isolated nucleic acid molecules of the inven-
tion include those polynucleotides encoding the above 
described CocE polypeptides. In other embodiments, the 
recombinant polypeptides of the invention disclosed herein 
are encoded by a nucleic acid that has at least 85% sequence 
identity (e.g., 85%,86%, 87%, 88%,89%, 90%, 91%,92%, 
93%, 94%, 95%, 96%, 97%, 98%, and 99%) with the nucleic 
acid sequence of SEQ ID NO: 2, where the expressed recom-
binant CocE polypeptide retains substantially the same or 
more catalytic efficiency of wild-type CocE polypeptide and 
has increased thermostability as compared to wild-type 
CocE. 
12 
dancy or degeneracy of the genetic code, encodes the same 
polypeptide as the polynucleotides of SEQ ID NOS: 3-37. 
Design of Mutant CocE 
CocE thermostabilizing mutations can be designed to 
either increase the thermodynamic stability of a polypeptide 
through lowering llG(unfolded~folded) or decrease rate of 
unfolding through increasing the activation free energy of the 
unfolding process. The llG(unfolded~folded) is the free-
energy difference between the unfolded and the folded state. 
10 For a thermodynamically stable polypeptide, 
llG(unfolded~folded) should be a negative value. Generally, 
the lower the llG(unfolded~folded) value, the more stable 
the folded state. The activation free energy of the unfolding 
process is the free energy difference between the folded state 
15 and the transition state of unfolding (Steipe, 1999). 
Mutant CocE polypeptides with increased thermo stability 
can be designed and generated by a variety of methods known 
to the art including, for example, rational design, directed 
evolution (e.g., random mutagenesis, mutagenesis of the 
20 CocE host organism), or a combination thereof. Directed 
evolution can be achieved through mutation and recombina-
tion followed by either screening for the desired trait or by 
applying a selective pressure to obtain the trait of interest (see 
e.g., Lehmann and Wyss, 2001). Mutagenesis can be per-
Nucleic acids that hybridize under stringent conditions to 
the nucleic acids of SEQ ID NO: 2 or the complements of 
SEQ ID NO: 2 can also be used in the invention. For example, 
such nucleic acids that hybridize to SEQ ID NO: 2 or the 
complement of SEQ ID NO: 2 under low stringency condi-
tions, moderate stringency conditions, or high stringency 
conditions and also encode a mutant CocE polypeptide that 
has esterase activity with increased thermostability as com-
pared to wild-type CocE, are within the invention. Preferred 
nucleic acids are those having a nucleotide sequence that is 
the complement of all or a portion of SEQ ID NO: 2. Other 
variants of the native CocE gene within the invention are 
polynucleotides that share at least 65% (e.g., 65%, 66%, 67%, 35 
68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 
78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 
98%, and 99%) sequence identity to SEQ ID NO: 2 or the 
complement of SEQ ID NO: 2. Nucleic acids that hybridize 
under stringent conditions to or share at least 65% sequence 
identity with SEQ ID NO: 2 or the complement of SEQ ID 
NO: 2 can be obtained by techniques known in the art such as 
25 formed either on the specific gene of interest or through 
mutagenesis and selection of a host organism such that the 
engineered property is conferred to the protein of interest. 
Preferably, the thermostability of CocE mutants are engi-
neered through a three-prong approach of (i) rational design 
30 through computation-guided site-directed mutagenesis (see 
e.g., Example 3; Example 4), (ii) random mutagenesis of the 
CocE gene and high throughput screening (see e.g., Example 
4; Example 15); and (iii) mutagenesis of the CocE host organ-
ism followed by genetic selection (see e.g., Example 14). 
Various rational design concepts are known to those of skill 
in the art to accomplish lowering llG(unfolded~folded) and/ 
or increasing the activation free energy of the unfolding pro-
cess (see e.g., Lehmarm, 2001). For example, one can: 
decrease the entropy of the unfolded state by introducing 
40 additional disulfide bridges or by X~ Pro mutations; increase 
a-helix propensity by Gly~Ala substitutions or by stabiliza-
tion of a-helix macrodipoles; improve electrostatic interac-
tions between charged surface residues by introducing addi-
tional salt bridges or even salt-bridge networks, or by by making mutations in the native CocE gene, or by isolation 
from an organism expressing such a nucleic acid (e.g., an 
allelic variant). 
Nucleic acid molecules encoding mutant CocE fusion pro-
teins are also within the invention. Such nucleic acids can be 
made by preparing a construct (e.g., an expression vector) 
that expresses mutant CocE fusion protein when introduced 
into a suitable host. For example, such a construct can be 
made by ligating a first polynucleotide encoding mutant 
CocE protein fused in frame with a second polynucleotide 
encoding another protein such that expression of the con-
struct in a suitable expression system yields a fusion protein. 
The nucleic acid molecules of the invention can be modi-
fied at a base moiety, sugar moiety, or the phosphate back-
bone, e.g., to improve stability of the molecule, hybridization, 
and the like. Nucleic acid molecules utilized in embodiments 
of the invention disclosed herein can be in the form of RNA or 
in the form of DNA (e.g., eDNA, genomic DNA, and syn-
thetic DNA). The DNA can be double-stranded or single-
stranded, and if single-stranded can be the coding (sense) 
strand or non -coding (anti -sense) strand. The coding 
sequence which encodes a mutant CocE polypeptide can be 
identical to the claimed nucleotide sequence, or it can also be 
a different coding sequence which, as a result of the redun-
45 thermo stabilizing mutations based on calculations of electro-
static potentials. 
Molecular modeling, based on appropriate molecular 
dynamics (MD) simulations, can rationally guide site-di-
rected mutagenesis so as to design mutant CocE polypeptides 
50 possessed of increased thermo stability. Classical MD simu-
lation enables the study of time evolution of a large system by 
taking many small successive time steps under atomic forces 
determined by a set of parameterized interaction functions 
(force field), including bonded interactions (bonds, angles, 
55 and dihedral angles), non-bonded van der Waals interactions, 
and electrostatic interactions based or net atomic charges. 
Due to the simple force field form, the MD simulation may be 
performed for a sufficiently long simulation time to give 
meaningful ensemble-averaged properties, even for a very 
60 large system involving over a hundred thousand atoms. So, 
for CocE and each proposed mutant, the MD simulation can 
lead to a reasonable, dynamically averaged 3D structure of 
the simulated polypeptide in water. 
One approach used successfully herein focuses on the 
65 rational design of thermo stabilizing mutations that lower the 
llG(unfolded~folded) value of the polypeptide (see e.g., 
Example 3). Such approach requires only the calculation of 
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llG(unfolded~folded), without performing a more time-
consuming computation on the structure and energetics of the 
transition state of the unfolding. Hence, to increase the ther-
mostability of a polypeptide before pegylation, one can use a 
method implemented in a rational design program (e.g., 
RosettaDesign) that uses an energy function for evaluating 
the fitness of a particular sequence for a given fold and a 
Monte Carlo search algorithm for sampling sequence space. 
Such approach is known to produce increased thermo stability 
of other enzymes with no reduction in catalytic efficiency (see 
e.g., Korkegian, 2005). For example, the fold used in the 
computation can correspond to that of the available CocE 
X-ray crystal structure. 
The rational design program allows prediction of a set of 
modified amino acid sequences that potentially have lower 
energies (e.g., the llG(unfolded~folded) values) and, there-
fore, higher thermo stability. Thus, one can use the computa-
tional design described herein to predict mutations in the 
CocE polypeptide core that can lead to thermostabilization of 
the polypeptide without loss of catalytic efficiency. This 
approach minimizes experimental test time and greatly 
increases the success of experimental outcomes. The pre-
dicted thermo stabilizing mutations can be tested individually 
by site-directed mutagenesis and then in combination, in an 
iterative process (see e.g., Example 15). 
14 
treatment with hydroxylamine has been used to generate ther-
mostable mutants of Bacillus polymyxa beta-glucosidase A 
(Lopez-Camacho et a!. (1996) Biochemistry Journal 314, 
833-838) and firefly luciferase (White eta!. (1996) Biochem-
istry Joumal319 (Pt 2), 343-350). 
Mutagenesis of the CocE host organism can also be used to 
generate thermostable CocE mutants. A simple and fast 
method for the production of thermostable CocE variants can 
be achieved by utilizing the enzyme's ability to confer 
10 metabolism of cocaine as a sole carbon source on its host 
organism. The CocE gene was originally sequenced from 
Rhodococcus MB1 by subcloning gene fragments into 
Rhodococcus erythropolis CW25, a bacterium unable to 
metabolize cocaine but able to grow on the cocaine esterase 
15 byproducts ecgonine methyl ester and benzoate (Bresler eta!. 
(2000) Applied & Environmental Microbiology 66, 
904-908). Another organism previously shown to metabolize 
cocaine byproducts is Pseudomonas jluorescens (MBER), 
which was able to grow in a symbiotic relationship with 
20 another bacterium able to metabolize cocaine via the esterase 
Comamonas acidovorans (MBLF). 
While difficult to transform with plasmids at high efficien-
cies, these bacterial strains can be relatively easily trans-
formed with the native CocE gene cloned into appropriate 
25 shuttle vectors and then traditional bacterial mutagenesis can 
be performed (see e.g., Example 14). Because these bacteria 
would normally only grow at 25-30° C. on cocaine hydrolysis 
products, selection for mutants able to metabolize cocaine 
efficiently at 37° C. would be expected to select for highly 
Directed evolution can also be used to generate thermo-
stable CocE mutants. Directed evolution encompasses a 
series of experimental techniques that produce accelerated 
diversity and adaptation through mutation and recombination 
followed by either screening for the desired trait or by apply-
ing a selective pressure to obtain the trait of interest (Leh-
mann & Wyss (2001) Current Opinion in Biotechnology 12, 
371-375). Thus directed evolution involves both a process to 
generate diversity and an efficient screening or selection 
method for the detection or enrichment of the desired trait. 35 
30 active and CocE mutants that are stable at 37° C. 
The exposure ofbacteria to radiation or chemical agents for 
the production of mutants carrying new phenotypes is well 
known in the art (see e.g., Maron, D. M. and Ames, B N 
(1983) Mutation Research 113, 173-215). Mutagenesis by 
irradiation can involve both ionizing and non-ionizing radia-
tion; however, non-ionization radiation is the widely used, Directed evolution has previously been successfully applied 
to the production of thermostable proteins, and the generation 
of diversity has been achieved through, for example, error 
prone PCR, saturation mutagenesis, DNA shuffling, chemical 
mutagenesis, and combinations thereof. Error prone PCR 
amplifies the gene of interest with non-proofreading poly-
merases and stressful conditions designed to randomly gen-
erate single base pair mutations. After each round the best 
mutants are selected and are used as parent sequences in the 
next round of mutagenesis. This technique has been used to 
generate a number of thermostable protein variants, including 
propyl endopeptidase (Uchiyama rna., et a!. 2000), betaglu-
curonidase (Flores, H. and A. D. Ellington (2002) Journal of 
Molecular Biology 315, 325-337) and family 10 xylanases 
(Andrews eta!. (2004) J Bioi Chern 279, 54369-79). Satura-
tion mutagenesis also amplifies the gene of interest but incor-
porates universal bases during amplification to generate a 
much higher number of mutations. This technique has been 
used to generate thermostability in a psychrophilic enzyme 
(Miyazaki eta!. (2000) Journal of Molecular Biology 297, 
1015-1026). DNA shuffling involves one or more cycles of 
recombination between a set of homologous sequences to 
obtain improved variants of a given enzyme. This technique 
can also be used in tandem with error-prone PCR, where the 
best mutants obtained by error-prone PCR are combined by 
DNA shuffling to generate a new subset of mutants. DNA 
shuffling has been implemented to generate thermostable 
variants ofbeta-glucuronidase (Flores, H. and A. D. Ellington 
(2002) Journal of Molecular Biology 315, 325-337). Chemi-
cal mutagenesis involves treating plasmid DNA with chemi-
cals that introduce point mutations into the sequence such as 
hydroxylamine, nitrosamines or dimethyl sulfate. Plasmid 
and UV radiation at 260 nm is most effective as a lethal agent. 
Mutagenesis is caused by the induction of pyrimidine dimers, 
increasing the likelihood of incorporating mismatches during 
40 replication. Cells are exposed to UV radiation at a dose pre-
determined to kill90-95% of the cell population, and mutants 
are then sought among the survivors. Chemical mutagenesis 
includes the use of base analogs such as 5-bromouracil and 
2-aminopurine which increase copy error during replication, 
45 or the use of agents that react directly with DNA such as 
hydroxylamine or nitrosoguanidine which induce mutations 
at a higher frequency than base analogs. 
Generating Mutant CocE Polypeptides 
Embodiments of the invention further pertain to methods 
50 of producing the mutant CocE polypeptides. For example, a 
host cell transfected with a nucleic acid vector directing 
expression of a nucleotide sequence encoding the mutant 
CocE polypeptides can be cultured under appropriate condi-
tions to allow expression of the peptide to occur. The cells can 
55 be harvested, lysed, and the protein isolated. A mutant CocE 
polypeptide can be isolated from host cells using techniques 
known in the art for purifYing proteins including ion-ex-
change chromatography, gel filtration chromatography, ultra-
filtration, electrophoresis, and immunoaffinity purification 
60 with antibodies specific for such protein (see e.g., Example 
1 ). 
For example, after a mutant CocE polypeptide has been 
expressed in a cell, it can be isolated using any immuno-
affinity chromatography. More specifically, an anti-CocE 
65 antibody can be immobilized on a colunm chromatography 
matrix, and the matrix can be used for immuno-affinity chro-
matography to purifY the mutant CocE polypeptide from cell 
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lysates by standard methods (see, e.g., Sambrook and Russel 
(2006) Condensed Protocols from Molecular Cloning: A 
Laboratory Manual, Cold Spring Harbor Laboratory Press, 
ISBN 0879697717). After immuno-affinity chromatography, 
the mutant CocE polypeptide can be further purified by other 5 
standard techniques, e.g., high performance liquid chroma-
tography. In another embodiment, a mutant CocE polypep-
tide is expressed as a fusion protein containing an affinity tag 
(e.g., Hisx6) that facilitates its purification (see e.g. Example 
16 
extended circulating time (Lasic, DD (1997) Journal of Con-
trolled Release 48, 203-222), as well as pegylated asparagi-
nase whose in vivo half-life has been drastically improved 
from 26 hours seen for free asparaginase to 15 days (Avramis 
eta!. (2002) Blood 99, 1986-1994). Further, it is recognized 
in the art that pegy lation can significantly enhance the thermal 
stability of an enzyme (Kazan, D. and Erarslan, A. (1997) 
Applied Biochemistry & Biotechnology 62, 1-13; Efremova 
et a!. (1998) Biochemistry (Moscow) 63, 441-447) and 
1 ). 
Pegylation of Mutant CocE Polypeptides 
The mutant CocE can be pegylated so as to increase the 
duration of action and heat stability, and decrease immuno-
genicity. Pegylation can further enhance the thermostability 
10 reduce activation of the complement system (Chang et a!. 
(2005) Bioconjugate Chemistry 16, 147-155). Thus, PEGy-
lation technology is well suited to improve the pharmacologi-
cal and pharmaceutical effects of the mutant CocE of the 
of the mutant CocE of the invention and increasing serum half 15 
life by decreasing renal clearance, proteolysis, macrophage 
uptake, and immunological response. 
invention (see e.g., Example 11). Pegylation of mutant CocE 
can also be used in conjunction with RBC encapsulation. 
Encapsulating Mutant CocE in RBC 
The mutant CocE can be encapsulated into red blood cells 
(RBC) so as to increase the duration of action and heat sta-
bility, and decrease immunogenicity. Cocaine, just as it rap-
idly crosses the blood-brain barrier, also rapidly transits the 
RBC plasma membrane, and this uptake has been demon-
strated in a study of intravenous cocaine administration in 
man (Javaid et a!. (1978) Journal of Chromatography 15, 
105-113). Furthermore, cocaine concentrations in RBC 
exceed the concentrations in plasma (Javaid et a!. (1978) 
Journal of Chromatography 15, 105-113). As such, RBC 
encapsulation can be utilized to shield thermostable forms of 
CocE from clearance. 
Erythrocytes have been exploited extensively for their 
potential applications as drug carriers (Wang et a!. (2002) 
Advanced Drug Delivery Reviews 54, 547-570). Being the 
most abundant cells of the human body, RBC offers 
unmatched advantages to function as a drug carrier. First, 
erythrocytes are completely biocompatible and biodegrad-
able, particularly when the autologous cells are used for drug 
loading. In addition, the biconcave disk shape of erythrocytes 
provides them with the highest surface to volume ratio (1.9x 
104 em/g) (Guyton, A G & Hall, J E (1996) Textbook of 
Medical Physiology, 425-433) usable for drug encapsulation. 
Pegylation is the process of attaching repeating units of 
ethylene glycol (i.e., polyethylene glycol, or PEG) to a 
polypeptide to reduce the polypeptide's immunogenicity and 20 
its rate of renal clearance (see generally (Veronese, F M and 
Harris, J M (2002b) Advanced Drug Delivery Reviews 54, 
457-606, Veronese, F M and Harris, J M (2002c) Advanced 
Drug Delivery Reviews 55, 1259-1345, reviewing PEGyla-
tion technology). Each ethylene glycol unit can bind to two or 25 
three water molecules, which effectively increases the size of 
the peptide, and can protect the peptide from immune 
responses, enzymatic degradation, and/or rapid renal clear-
ance. The polyethylene glycol can also stabilize against 
changes in temperature and pH. The net result is that the 30 
therapeutic polypeptide can be maintained longer in the 
blood, and induces a lesser immune response (Harris, J M and 
Chess, R B (2003) Nature Reviews. Drug Discovery 2, 214-
221). PEG possesses a unique set of properties, including 
absence of toxicity, antigenicity, and immunogenicity, a 35 
mass-dependent diminution of renal clearance, and a high 
flexibility and solubility in water. It imparts these character-
istics to the proteins to which it is bound (Veronese, F M and 
Harris, J M (2002b) Advanced Drug Delivery Reviews 54, 
457-606). 
A PEG polymer can first be activated with a functional 
group that encourages covalent binding to an amino acid of 
the protein. The terminal hydroxyl group of the PEG can be 
modified by an active carbonate, active ester, aldehyde or 
tresylate derivative. The PEG can be attached to lysines or to 45 
introduced cysteine residues of the mutant CocE. Repeating 
units of ethylene oxide can be constructed in many configu-
rations having different lengths, with or without branching, 
and with various molecular weights. Means of incorporation 
can include site-directed mutagensis or use of maleimide 50 
derivatives of trans glutaminase. 
40 Encapsulation in RBC also prevents the loaded drug from 
inactivation by endogenous factors as well as protects the 
organisms from toxic effects of the encapsulated drug (Wang 
eta!. (2002)Advanced Drug Delivery Reviews 54, 547-570). 
PEG is FDA approved for use as a vehicle or base in 
pharmaceuticals, including injectable, topical, rectal and 
nasal formulations (Harris and Chess, 2003). And PEGylated 
drugs have been approved for clinical use (see e.g., PEG- 55 
interferon alpha-2a (Hamidi, M and Tajerzadeh, H (2003) 
Drug Delivery 10, 9-20; PEG-interferon alpha-2b (Reddy et 
a!. (2002) Advanced Drug Delivery Reviews 54, 571-586). 
Owing to the unparallel spatial dynamic mobility of PEG, 
modification of the surface of a mutant CocE by the PEG 60 
polymer can shield the coated enzyme from actions by the 
proteolytic enzymes and recognition by the immune system; 
thereby reducing the immunogenicity and prolonging the 
circulating half-life ofthepegylatedmutant CocE. Success of 
pegylation strategies include PEG-modified liposomes (i.e., 65 
stealth liposomes, so termed due to their ability in dodging 
immune detection and renal clearance to yield a significantly 
Furthermore, RBC encapsulation enables avoidance of unde-
sirable immune responses (i.e. antigenicity and immunoge-
nicity) that may be triggered by foreign bodies (Wang eta!. 
(2002) Advanced Drug Delivery Reviews 54, 54 7 -570). And, 
erythrocytes possess longer circulation half-life in compari-
son to other synthetic carriers. For example, the normal life-
span of an erythrocyte in systemic circulation is reported to be 
about 120 days (Guyton, A G & Hall, J E (1996) Textbook of 
Medical Physiology, 425-433). 
Encapsulation of mutant CocE in erythrocytes can be 
according to several techniques known in the art, including 
electroporation, drug (e.g., primaquine )-induced endocyto-
sis, and osmosis (see e.g., Green, R. and Widder, K J (1987) 
Methods In Enzymology, Vol. 149). These methods can 
include swelling and disrupting the cell membrane, releasing 
the interior content including primarily hemoglobin and also 
cytoskeleton, entrapping the drug, and then resealing the 
membrane to yield the cup-shaped, spherical, pink or white-
colored RBC (generally termed "RBC-Ghost"). 
Alternatively, membrane-penetrating peptides can be 
employed to encapsulate mutant CocE in erythrocytes (see 
e.g., Example 12). Membrane-penetrating peptides, or pro-
tein transduction domain (PTD) peptides are a family of small 
(normally consists of 10-15 amino acid residues) peptides 
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including TAT, LMWP, and other arginine-rich cationic pep-
tides (see generally, Dietz, G P H and Bahr, M (2004) 
Molecular Cell Neurosciences 27, 85-131). It is known to the 
art that, by covalently linking PTD to almost any type of 
molecular species including proteins (MW> 150 kDa; more 
than 60 different proteins have already been tested (Dietz, G 
PH and Bahr, M (2004) Molecular Cell Neurosciences 27, 
85-131) andnano-carriers ( e.g.liposomes ), PTD can ferry the 
attached species across cell membrane of all organ types 
including the brain (Schwarze et a!. (1999) Science 285, 10 
1569-1572). PTD is neither toxic nor immunogenic 
(Schwarze et a!. (1999) Science 285, 1569-1572), and the 
PTD-mediated cell internalization does not induce perturba-
tionor alteration of the erythrocytes cell membrane (Suzuki et 15 
a!. (2002) Journal of Biological Chemistry 25, 2437 -2443). 
PTD has been used successfully in protein loading RBC, and 
results in erythrocytes with unaltered physical and chemical 
attributes (see e.g., Li eta!. (2003) American Pharmaceutical 
Review 6, 22-26). Thus, PTD peptide conjugation to mutant 20 
CocE can facilitate RBC encapsulation. RBC encapsulation 
can also be carried out by using pegylated mutant CocE. 
Stabilizing Mutant CocE 
Another aspect of the invention is directed toward stabili-
zation of mutant CocE polypeptides using substrates, prod- 25 
ucts, and/or inhibitors of cocaine. Substrates and products 
useful in embodiments disclosed herein include, for example, 
but are not limited to, cocaine; cocaine derivatives, such as, 
for example, (-)-cocaine, (+)-cocaine, tropacocaine, and the 
like; thio-cocaine derivatives, such as, for example, Thiol-1, 30 
Thiol-2, and the like; amide-cocaine derivatives; provitamin-
cocaine derivatives, such as PABA cocaine, Niacin cocaine, 
and the like; benzoic acid; 4-nitrophenyl acetate (4NPA); 
4-nitrophenol (4NP); and the like. Exemplary inhibitors 
include, but are not limited to, substrate analogues, such as, 35 
phospho-fluorococaine, 0-Phospho-cocaine, 0-methylphos-
phococaine, S-Methylphophococaine, and the like; product 
analogues, such as, Ecgonine and Ecgonine derivatives, such 
as, boronic acid ecogonine methylester analog; phenylbo-
ronic acid; benzoic acid derivatives, such as, 4-tert-Butyl 40 
benzoic acid, 1-Naphthoic acid, 2,3,4-trimethyl-benzoic acid 
methyl ester, and the like. Additional chemicals include, for 
example, but are not limited to, SDS, glycerol, PEG, and the 
like. 
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Treatment Methods 
Another aspect of the invention is directed toward catalytic 
degradation approach to anti-cocaine therapeutics. Provided 
are treatments, both prophylactic and therapeutic, of cocaine-
induced conditions through the administration of thermo-
stable, esterase active, mutant CocE polypeptides to a subject 
in need thereof. The cocaine esterase variants of the invention 
hold significant clinical value because of their increased ther-
mostability and longer plasma half-life than known naturally 
occurring CocE. It is this increase in thermostability and 
plasma half-life that enables a much more rapid response to 
the life-threatening symptoms of cocaine toxicity that sets the 
CocE variants of the invention apart from other treatment 
options. 
A determination of the need for treatment will typically be 
assessed by a history and physical exam consistent with the 
cocaine-induced condition. Cocaine-induced conditions 
include, but are not limited to, cocaine overdose, cocaine 
toxicity, and cocaine dependence and/or addiction. For 
example, the diagnosis of cocaine toxicity can include con-
vulsions, grand-mal seizures, cardiac arrest, myocardial inf-
arction, cardiac arrhythmias, increased blood pressure, 
stroke, drug-induced psychosis, dissecting aneurysm, and 
increased myocardial oxygen demand. As another example, 
in the case of cocaine dependence and/or addiction, with-
drawal symptoms include subjective sensations of mild to 
severe dysphora, depression, anxiety, or irritability. Subjects 
with an identified need of therapy include those with a diag-
nosed cocaine-induced condition, an indication of a cocaine-
induced condition, and subjects who have been treated, are 
being treated, or will be treated for a cocaine-induced condi-
tion. The subject is preferably an animal, including, but not 
limited to, mammals, reptiles, and avians, more preferably 
horses, cows, dogs, cats, sheep, pigs, and chickens, and most 
preferably human. 
An effective amount of the mutant CocE polypeptides 
described herein is generally that which can reduce the 
cocaine-toxicity or the severity of a cocaine-induced condi-
tion. Reduction in severity includes, for example, an arrest or 
a decrease in symptoms, physiological indicators, biochemi-
cal markers, or metabolic indicators. When used in the meth-
ods of the invention, a therapeutically effective amount of 
mutant CocE polypeptide described herein can be employed 
in pure form or, where such forms exist, in pharmaceutically 
45 acceptable salt form and with or without a pharmaceutically 
acceptable excipient. For example, the mutant CocE polypep-
tides of the invention can be administered at a reasonable 
benefit/risk ratio applicable to any medical treatment, in an 
Preferably, the substrates, products, and/or inhibitors sta-
bilize thermal denaturation of the polypeptides disclosed 
herein. In some embodiments, the substrates, products and/or 
inhibitors also prevent thermally-induced aggregation in gel 
electrophoresis. Generally, use of a substrate, product, and/or 
inhibitor results in at least about a 10% increase in stability 50 
and/or inhibition, respectively. For example the increase can 
be about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 
60%,65%,70%,75%,80%,85%, 90%, 95%, 100%, 120%, 
150%, 200%, 300%, or even 500% or greater. Thus, sub-
strates, products, and/or inhibitors are well suited to stabilize 55 
the mutant CocE polypeptides disclosed herein (see e.g., 
Example 20). 
In one embodiment, small molecules are used to thermo-
stabilize the mutant CocE polypeptides disclosed herein. In a 
preferred embodiment, such molecules do not occupy the 60 
active site of the polypeptide. 
In some embodiments, the polypeptides disclosed herein 
can be co-infused with a stabilizing molecule. In other 
embodiments, the stabilizing molecules can be used to stabi-
lize the polypeptide during manufacturing. In still other 65 
embodiments, the stabilizing molecules can be used to stabi-
lize the mutant CocE polypeptides until ready for use. 
amount sufficient to substantially reduce the cocaine concen-
tration in the blood and/or tissues of the subject. 
Toxicity and therapeutic efficacy of mutant CocE polypep-
tides can be determined by standard pharmaceutical proce-
dures in cell cultures and/or experimental animals for deter-
mining the LD50 (the dose lethal to 50% of the population) 
and the ED 5 0 , (the dose therapeutically effective in 50% of the 
population). The dose ratio between toxic and therapeutic 
effects is the therapeutic index that can be expressed as the 
ratio LD50/ED50, where large therapeutic indices are pre-
ferred. 
The amount of mutated CocE polypeptide that can be com-
bined with a pharmaceutically acceptable carrier to produce a 
single dosage form will vary depending upon the host treated 
and the particular mode of administration. It will be appreci-
ated by those skilled in the art that the unit content of agent 
contained in an individual dose of each dosage form need not 
in itself constitute a therapeutically effective amount, as the 
necessary therapeutically effective amount could be reached 
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by administration of a number of individual doses. Agent 
administration can occur as a single event or over a time 
course of treatment. For example, an agent can be adminis-
tered daily, weekly, bi-weekly, or monthly. For some condi-
tions, treatment could extend from several weeks to several 
months or even a year or more. 
The specific therapeutically effective dose level for any 
particular subject will depend upon a variety of factors 
including the cocaine-induced condition being treated and the 
severity of the cocaine-induced condition; activity of the 10 
mutant CocE polypeptide employed; the specific composi-
tion employed; the age, body weight, general health, sex and 
diet of the patient; the time of administration; the route of 
administration; the plasma half-life of the mutant CocE 
polypeptide; the rate of excretion of the mutant CocE 15 
polypeptide employed; the duration of the treatment; drugs 
used in combination or coincidental with the mutant CocE 
polypeptide employed; and like factors well known in the 
medical arts (see e.g., Koda-Kimble et a!. (2004) Applied 
Therapeutics: The Clinical Use of Drugs, Lippincott Will- 20 
iams & Wilkins, ISBN 0781748453; Winter (2003) Basic 
Clinical Pharmacokinetics, 4'h ed., Lippincott Williams & 
Wilkins, ISBN 0781741475; Sharqel (2004) Applied Biop-
harmaceutics & Pharmacokinetics, McGraw-Hill/Appleton 
& Lange, ISBN 0071375503). It will be understood by a 25 
skilled practitioner that the total daily usage of the mutant 
CocE polypeptide for use in embodiments of the invention 
disclosed herein will be decided by the attending physician 
within the scope of sound medical judgment. 
Mutant CocE polypeptides described herein can also be 30 
used in combination with other therapeutic modalities. Thus, 
in addition to the therapies described herein, one can also 
provide to the subject other therapies known to be efficacious 
for particular cocaine-induced conditions. 
The mutant CocE polypeptides described herein can be 35 
formulated by any conventional marmer using one or more 
pharmaceutically acceptable carriers and/or excipients (see 
e.g., Gennaro (2005) Remington the Science and Practice of 
Pharmacy 21st ed. Lippincott Williams & Wilkins, ISBN 
0781746736). Such formulations will contain a therapeuti- 40 
cally effective amount of the mutant CocE polypeptide, pref-
erably in purified form, together with a suitable amount of 
carrier so as to provide the form for proper administration to 
the subject. The formulation should suit the mode of admin-
istration. Mutant CocE polypeptides of use with the current 45 
invention can be formulated by known methods for adminis-
tration to a subject using several routes which include, but are 
not limited to, parenteral, pulmonary, oral, topical, intrader-
mal, intramuscular, intraperitoneal, intravenous, subcutane-
ous, intranasal, epidural, ophthalmic, buccal, and rectal. The 50 
mutant CocE polypeptide can also be administered in com-
bination with one or more additional agents disclosed herein 
and/or together with other biologically active or biologically 
inert agents. Such biologically active or inert agents can be in 
fluid or mechanical communication with the agent(s) or 55 
attached to the agent(s) by ionic, covalent, Van der Waals, 
hydrophobic, hydrophillic or other physical forces. 
Mutant CocE polypeptides described herein can be admin-
istered parenterally, including intravenous, intramuscular, 
subcutaneous, and intraperitoneal injections. Excipients, 60 
commonly used in the parenteral delivery of small drug mol-
ecules, including solubility enhancers, osmotic agents, buff-
ers, and preservatives, can also be included in biomolecule 
formulations. Inclusion of antiaggregation and antiadsorp-
tion agents, such as surfactants and albumin, when formulat- 65 
ing and delivering biomolecules can add increased stability 
and decrease the risk of the active biomolecule interacting 
20 
with an interface, which can lead to unfolding, aggregation, 
and/or precipitation. The mutant CocE polypeptide can be 
lyophilized for added stability during storage, and re-pro-
cessed before parenteral administration. 
Preferably, the mutant CocE polypeptide is pegylated, thus 
providing increased stability and lessened immunogenicity 
(see above). 
Pulmonary delivery of macromolecules, such as mutant 
CocE polypeptides, provide for relatively easy, non-invasive 
administration to the circulatory system for systemic distri-
bution (see e.g., Cryan (2004)AAPS J. 7(1) article 4, E20-41, 
providing a review of pulmonary delivery technology). 
Advantages of pulmonary delivery include noninvasiveness, 
large surface area for absorption (-75m2), thin (-0.1 to 0.5 
f.tm) alveolar epitheliuem permitting rapid absorption, 
absence of first pass metabolism, decreased proteolytic activ-
ity, rapid onset of action, and high bioavailablity. Various 
inhalation delivery devices, such as metered-dose inhalers, 
nebulizers, and dry-powder inhalers, that can be used to 
deliver the biomolecules described herein are known to the art 
(e.g., AErx (Aradigm, CA); Respimat (Boehringer, Ger-
many); AeroDose (Aerogen Inc., CA)). Dry powder inhala-
tion devices are particularly preferred for pulmonary delivery 
of protein-based agents (e.g., Spinhaler (Fisons Pharmaceu-
ticals, NY); Rotohaler (GSK, NC); Diskhaler (GSK, NC); 
Spiros (Dura Pharmaceuticals, CA); Nektar (Nektar Pharma-
ceuticals, CA)). 
Controlled-release (or sustained-release) preparations can 
be formulated to extend the activity of the mutant CocE 
polypeptide and reduce dosage frequency. Controlled-release 
preparations can also be used to effect the time of onset of 
action or other characteristics, such as blood levels of the 
agent, and consequently affect the occurrence of side effects. 
Controlled-release preparations can be designed to initially 
release an amount of mutant CocE polypeptide that produces 
the desired therapeutic effect, and gradually and continually 
release other amounts to maintain the level of therapeutic 
effect over an extended period of time. In order to maintain a 
near-constant level of mutant CocE polypeptide in the body, 
the agent can be released from the dosage form at a rate that 
will replace the amount of agent being metabolized and/or 
excreted from the body. The controlled-release of an agent 
can be stimulated by various inducers, e.g., change in pH, 
change in temperature, enzymes, water, or other physiologi-
cal conditions or molecules. 
Controlled-release systems can include, for example, an 
infusion pump which can be used to administer the agent in a 
manner similar to that used for delivering insulin or chemo-
therapy to specific organs or tumors. The agents of the inven-
tion can be administered by other controlled-release means or 
delivery devices that are well known to those of ordinary skill 
in the art, including, for example, hydropropylmethyl cellu-
lose, other polymer matrices, gels, permeable membranes, 
osmotic systems, depots, multilayer coatings, microparticles, 
liposomes, micro spheres, or the like, or a combination of any 
of the above to provide the desired release profile in varying 
proportions. Other methods of controlled-release delivery of 
agents will be known to the skilled artisan and are within the 
scope of the invention. 
Mutant CocE polypeptides can be encapsulated and 
administered in a variety of carrier delivery systems. Carrier-
based systems for biomolecular agent delivery can: provide 
for intracellular delivery; tailor biomolecule/agent release 
rates; increase the proportion ofbiomolecule that reaches its 
site of action; improve the transport of the drug to its site of 
action; allow colocalized deposition with other agents or 
excipients; improve the stability of the agent in vivo; prolong 
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the residence time of the agent at its site of action by reducing 
clearance; decrease the nonspecific delivery of the agent to 
nontarget tissues; decrease irritation caused by the agent; 
decrease toxicity due to high initial doses of the agent; alter 
the immunogenicity of the agent; decrease dosage frequency, 
improve taste of the product; and/or improve shelflife of the 
product. 
Examples of carrier delivery systems for with mutant CocE 
polypeptides described herein include microspheres (see e.g., 
Yarde & Pack (2004) Expert Opin. Bioi. 4(1) 35-51), hydro-
gels (see generally, Sakiyama et a!. (2001) FASEB J. 15, 
1300-1302), polymeric implants (see generally, Teng eta! 
(2002) Proc. Nat!. Acad. Sci. U.S.A. 99, 3024-3029), smart 
polymeric carriers (see generally, Stayton et a!. (2005) 
Orthod Craniofacial Res 8, 219-225; Wu eta!. (2005) Nature 
Biotech (2005) 23(9), 1137-1146), and liposomes (see e.g., 
Galovic eta!. (2002) Eur. J. Pharm. Sci. 15, 441-448; Wagner 
eta!. (2002) J. Liposome Res. 12, 259-270). Preferably, the 
mutant CocE polypeptide is encapsulated in RBC (see above; 
Example 12). 
Screening Methods 
Another aspect of the invention is directed toward screen-
ing methods for the generation, identification, and purifica-
tion of thermostable mutant CocE polypeptides. Generally, 
mutant CocE polypeptides can be initially designed accord-
ing to the approaches described above. Such designed 
polypeptides can then be screened for preferred characteris-
tics, such as retention ofhydrolytic efficiency, increased ther-
mostability, increased plasma-half-life, and/or reduced anti-
genicity. Also, random mutant CocE polypeptides can be 
screened for the desired characteristics. 
22 
The esterase activity of the cultured cells or isolated mutant 
polypeptide can be subsequently measured at one or more 
temperatures to determine the thermo stability of the mutants. 
The temperature at which the activity assay is performed 
determines the degree of thermostability detection. Thus, 
while the final mutants will preferably have a melting tem-
perature of 45° C. or higher (as determined by, for example, 
circular dichroism), often, the initial screening at 45° C. will 
not find active enzymes. Rather, several cycles of mutagen-
10 esis and screening at subsequently increasing temperatures 
can be performed to achieve thermostable mutants. Thus, 
initial screening can be performed at 30° C., and after further 
cycles of mutagenesis, screening can be performed with 
incrementally increasing temperatures (for example, 34° C., 
15 37° C., 40° C., 42.5° C., 45° C., etc.), until a mutant of suitable 
thermostability is achieved. The incremental temperature 
increases are determined empirically during the procedure, 
and are affected by the number of hits at particular tempera-
tures and the determined Tm of the generated mutants. 
20 While under no obligation to do so, and while not wishing 
to be bound by theory, herein follows what is believed to be a 
mechanistic explanation of melting of various embodiments 
of mutant CocE polypeptides described herein. CD spectra 
data illustrate that the CD melting of cocaine esterase and 
25 mutants is irreversible, as cooling to 0 degrees does not 
reform the original spectra (see, e.g., Example 19). While 
thermodynamic parameters cannot be ascertained, CD spec-
tra can be used to comparatively determine whether mutants 
are more or less stable, whether they have different secondary 
30 structures or aggregation properties. It is believed that the 
CocE polypeptides described herein melt via an intermediate 
step, that is, the polypeptides undergo a 2-step melting pro-
cess. 
Detection methods to screen for thermostable mutants 
encompass a wide variety of techniques. The following is an 
exemplary summary of a generic protocol. Nucleic acid 
encoding the mutant CocE polypeptides (generated, for 35 
example, through rational design, random mutagenesis, or 
host mutagensis) is transformed into an appropriate expres-
sionhost (for example, E. coli cells such as E. coli BL21 Gold 
(Stratagene)), and expression of the mutant polypeptide is 
induced according to standard protocols (e.g. by IPTG). 40 
Expression is performed at temperatures to produce optimal 
protein expression (e.g., 16° C. forCocE, see e.g., Example 1) 
for a pre-determined period of time (e.g., anywhere from 30 
minutes to 24 hours or longer). Alternatively, expression is 
performed at an elevated temperature (for example, the 45 
elevated temperature can be at least about 35° C., at least 
about 36° C., at least about 37° C., at least about 38° C., at 
least about 39° C., at least about 40° C., or even higher). 
Preferably, the elevated temperature at which mutated CocE 
polypeptide is expressed is 37° C. Around this temperature, 50 
wild-type CocE polypeptide partitions almost exclusively 
into inclusion bodies. Cells containing the expressed mutant 
polypeptides are screened for the presence of thermostable 
variants of CocE. 
Detection of esterase activity can be performed using a 
variety of methods, where substrates are coupled to a specific 
detection system. Appropriate substrates for use in determin-
ing esterase activity can include cocaine, tritiated (3H) 
cocaine, cocaine substrate derivatives such as a thio-cocaine 
derivative (see e.g., FIG. 6), and/or substrates that report 
general esterase activity such as 4-nitrophenyl acetate. The 
detection system can be directly coupled to the specifics of the 
substrate, for example: cleavage of uumodified cocaine can 
be detected by monitoring changes in cocaine absorbance at 
240 urn (see e.g., Example 4), or by monitoring pH changes 
that result from the accumulation of the acidic benzoic acid 
product (see e.g., Example 15), or through the use of cocaine 
aptamers (see e.g., Stojanovic, M. N., de Prada, P. & Landry, 
D. W. (2001) JAm Chern Soc 123, 4928-4931; Stojanovic, M. 
N. & Landry, D. W. (2002) JAm Chern Soc 124, 9678-9679) 
by monitoring changes in fluorescence upon degradation of 
cocaine (see example 15); cleavage of tritiated (3H) cocaine 
can be detected by acidification and detection of tritiated 
benzoic acid product through separation by chromatography 
(see example 1 and 15); cleavage of cocaine derivatives such 
Screening for the presence of thermostable variants of 
CocE generally involves either direct measurement on cul-
tured cells, on cell lysates, or following cellular disruption 
and isolation of the mutant CocE polypeptide. Cellular dis-
ruption can include osmotic shock, chemical lysis, sonicia-
tion, and/or homogenization, and isolation of the mutant 
polypeptide can be obtained through numerous methods 
including either direct absorption to a matrix or affinity 
absorption through the use of anti-cocaine antibodies or 
fusion-protein specific capture systems. Suitable matrix for 
absorption includes nitrocellulose paper, filters, untreated or 
affinity-treated microtiter plates, agarose or sepharose resins, 
and/or affinity-coated tips. 
55 as thio-cocaine can be monitored by the detection of reactive 
sulfhydryl groups, through the addition of Ellman's reagent 
and determination of absorbance changes at 412 nm (see e. g., 
Example 15), or by the addition and visualization of precipi-
tating sulfhydryl reacting heavy metals; cleavage of 4-nitro-
60 phenyl acetate can be detected by monitoring changes in 
absorbance at 420 nm (see e.g., Halgasova, N. eta!. (1994) 
Biochem J 298 Pt 3, 751-755; O'Conner, C. J. & Manuel, R. 
D. (1993) J Dairy Sci. 76, 3674-3682). 
Mutant CocE polypeptides identified through the above 
65 procedures, or a similar high throughput assay, can be further 
evaluated using in vitro procedures described herein (e.g., 
Kcat and Km values, stability at 37°, melting temperature 
US 9,200,265 B2 
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(Tm), endotoxin levels, ability to degrade cocaine in plasma). 
Mutant CocE polypeptides with thermostable esterase activ-
24 
ity and/or reduced immunogenicity, can be further evaluated 
using in vivo procedures described herein (e. g., potency, 
duration of action, effects with repeated dosing, and/or 
immunological evaluation). Preferably, mutant CocE 
polypeptides magnitudinal decrease of cocaine toxicity is 
examined first (see e.g., Examples 5, 7, and 8), and those 
mutants that reduce toxicity by at least about 5-l 0 fold can be 
further evaluated for time course of action (see e.g., Example 10 
6). Candidate mutant CocE polypeptides can be further sta-
bilized by, for example, pegylation and/or encapsulation in 
RBC and re-evaluated in the above described procedures. 
Max 190 plate reader (Molecular Devices) using SOFTmax 
Pro software (v1.13). The reaction was initiated by adding 
150 f.LL of a 2x enzyme solution to the 150 f.LL of a 2x cocaine 
solution. Final CocE concentrations ranged from 100 ng/mL 
to 20 ng/mL. Final cocaine concentrations were as follows: 
250, 126, 62.5, 31.25, 15.63, 7.81, 3.91, and 1.95 f.LM. For the 
kinetics of all enzymes, the buffer was phosphate buffered 
saline, pH 7.4. Initial rates were fitted to the Michaelis-
Menten equation, with kcat and Km as adjustable parameters 
(GraphPad; PRISM, v4). 
As determined using the cocaine spectrophotometric 
assay, the purified wild-type CocE polypeptide hydrolyzes 
cocaine with a Kcat of approx. 500 min- 1 and a Km of approx. 
2 f.LM, which is consistent with previously reported values 
(see e.g., Turner eta!. 2000). 
Having described the invention in detail, it will be apparent 
that modifications, variations, and equivalent embodiments 15 
are possible without departing the scope of the invention 
defined in the appended claims. Furthermore, it should be 
appreciated that all examples in the present disclosure are 
provided as non-limiting examples. 
Such expression procedures can be utilized for the mutant 
CocE polypeptides described herein. 
Example 2 
EXAMPLES 
The following non-limiting examples are provided to fur-
ther illustrate various embodiments of the invention disclosed 
herein. It should be appreciated by those of skill in the art that 
the techniques disclosed in the examples that follow represent 
approaches the inventors have found function well in the 
practice of the invention, and thus can be considered to con-
stitute examples of modes for its practice. However, those of 
skill in the art should, in light of the present disclosure, 
appreciate that many changes can be made in the specific 
embodiments that are disclosed and still obtain a like or 
similar result without departing from the spirit and scope of 
the invention. 
Example 1 
CocE Expression 
A method for expression and purification of CocE was 
established, where CocE is expressed in E. Coli as a fusion 
protein with a carboxyl terminus Hisx6-tag. The cocaine 
esterase gene was subcloned into theE. coli expression vector 
pET-22b( +)and high levels of cocaine esterase enzyme con-
taining a C-terminal histidine tag were induced upon the 
addition ofiPTG at 23 C. The recombinant protein accumu-
lated to approximately 10-15% of total protein. CocE was 
enriched on either a cobalt-chelate column (Talon™ Cion-
tech) or a nickel-chelated agarose colunm (Pierce) by virtue 
of the Hisx6 tag. The eluted protein was approximately 95% 
pure by SDS-PAGE and Coomassie blue staining, and was 
subsequently resolved by ion-exchange chromatography 
FPLC column (Q-Sepharose) using an NaCI gradient. The 
protein eluted as a single peak was approximately 99% pure, 
as indexed by SDS-PAGE and Coomassie blue staining (see 
e.g., FIG. 3). 
Enzyme activity was determined through two assays: a 
radio-ligand activity assay in which tritated cocaine was 
hydrolyzed and then after acidification, the tritiated benzoic 
acid product was separated from tritiated cocaine hydrochlo-
ride by chromatography; and a spectrophotometric assay 
under similar conditions as described by Turner eta!. (2002) 
Biochemistry 41, 12297-12307. The unique absorption spec-
tra of cocaine (extinction coefficient 6. 7 Llmmol/cm, at 240 
nm) allows for the observation of remaining cocaine follow-
ing enzymatic cleavage. The initial linear rates of decay of 
cocaine, representing velocity, were determined in a Spectra-
20 
Ex Vivo CocE Plasma Activity 
Ex vivo determination of cocaine levels following cocaine 
esterase was examined in human plasma (University of 
25 Michigan Hospital blood bank). Cocaine was obtained from 
The National Institute of Drug Abuse (Bethesda, Md., USA). 
Cocaine was dissolved in sterile water. Aliquots (3 ml) of 
human plasma were maintained at 37° C. in a water bath for 
1 0 minutes prior to the start and for the duration of the experi-
30 ment. After equilibrating plasma in water bath, cocaine was 
added to a final concentration of300 f.LM and vortexed for 30 
seconds. Plasma samples were removed and placed in a 
microcentrifuge tube containing the internal standard and a 
saturated sodium fluoride solution to prevent further cocaine 
35 metabolism. Immediately after taking the first plasma ample 
(cocaine alone), 0.05 mg/ml CocE or vehicle CocE was added 
and vortexed. Plasma samples were collected at 1, 2, 4, 6, 8, 
10, 15, 30, 45, 60, and 120 minutes after adding CocE. Levels 
of cocaine were measured using high performance liquid 
40 chromatography tandem mass spectrometry. 
Liquid chromatography was performed using a Surveyor 
HPLC system (Thermo Electron Corp., Franklin, Mass.) with 
a quanternary pump and auto sampler configured with a 10 fll 
injection loop. Separation was achieved using a Phenomex 
45 CIS 3 f.tm 30x4.6 mm column with corresponding guard 
column (Waters Corp., Milford, Mass.) at a flow rate of 600 
fll/min. Solvent A consisted of a 0.1% formic acid solution, 
and solvent B was 0.1% formic acid in acetonitrile (high 
purity grade; Burdick and Jackson, Muskegon, Mich.). A 3 
so minute ballistic gradient was used with cocaine and the inter-
nal standard co-eluting at 2.3 min. 
For detection and quantification by mass spectrometry, a 
Finnigan TSQ Quantum Ultra AM triple quadrapole mass 
spectrometer equipped with an IonMax electrospray ioniza-
55 tion source (ThermoE!ectron Corp., Franklin, Mass.) was 
used in positive ion, selected reaction monitoring mode. 
Nitrogen served as the nebulizing gas and argon as the colli-
sion gas. Gas flow rates, spray voltages, and collision energies 
were optimized. Calibration curves were determined for 
60 cocaine with 50 nM deuterated cocaine (cocaine D3 ) as the 
internal standard in untreated plasma samples. Unknown 
samples were also spiked with cocaine D3 . All samples were 
evaluated in triplicate. Standard curves and unknowns were 
analyzed by Quan Browser program in Xcalibur version 1.4 
65 (ThermoE!ectron Corp., Franklin, Mass.) software. Calibra-
tion curves were constructed using linear regression of 
cocaine peak area/internal standard area ratio as a function of 
US 9,200,265 B2 
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standard concentration with a weighting factor of 1/x. Stan-
dard curve fit values were accepted at a value is greater than 
0.99, and RSD values for replicate samples are between 
0-10%. 
26 
sand atoms. So, for CocE and each proposed mutant, the MD 
simulation will lead to a reasonable, dynamically averaged 
3D structure of the simulated polypeptide in water. 
Based on the X-ray crystal structure (PDB code 1JU3) of 
the bacterial cocaine esterase (CocE) (Larson et a!. (2002) 
Nature 9, 17), a complete 3D model of CocE binding with 
(-)-cocaine suitable for computational modeling its thermo-
dynamic stability was built. To increase the thermostability of 
CocE, a computational method was implemented in Rosetta-
Design program (Kuhlman and Baker (2000) PNAS 97, 
10383) capable of predicting thermostabilizing mutations 
within a given fold while minimizing any shift in the back-
bone that might structurally disrupt the active site structure or 
Results demonstrate that CocE is able to degrade cocaine 5 
very rapidly when the two are mixed briefly in human plasma 
(see e.g., FIG. 4). The first time point indicates the cocaine 
concentration prior to the addition of cocaine esterase or 
esterase vehicle. Prior to esterase treatment, cocaine levels 
were similar, but within 1 min of cocaine esterase adminis- 10 
tration, cocaine levels were decreased at least 100-fold to 
approximately 2 f.LM as compared with the vehicle-treated 
plasma sample. Cocaine levels continued to decrease in the 
esterase-treated plasma samples, falling below 1 microM by 
the 2-minute timepoint. 
The therapeutic efficiency of the enzyme was demon-
strated by the increasing dose of cocaine required to produce 
toxic effects after a single intravenous injection ofCocE. The 
wild-type enzyme demonstrated rapid kinetics for cocaine 
degradation ex vivo in rat and human serum. Two inactive 20 
mutants of CocE failed to protect the rats from the toxic 
effects of cocaine, confirming the protective effects are due to 
hydrolytic activity. Furthermore, CocE did not change the 
lethality of WIN-35065-2, a cocaine analog that lacks the 
benzoyl ester moiety targeted by CocE. The in vivo and ex 25 
vivo characterization ofCocE supports the role of the enzyme 
15 quench its flexibility. The method implemented in the Roset-
taDesign program uses an energy function for evaluating the 
fitness of a particular sequence for a given fold and a Monte 
Carlo search algorithm for sampling sequence space. A simi-
as a suitable antidote to toxicity in humans. 
Example 3 
Predicted Thermostable Mutant CocE 
Rational design of mutant CocE described herein was 
based upon molecular dynamics (MD) simulations. A com-
putational model of CocE was constructed using the pub-
lished crystal structure of wild-type CocE (see e.g., FIG. 2). 
Such models can be used to identify certain amino acid modi-
fications that increase the theoretical melting temperature of 
the protein without disrupting the structure at the active site. 
Classical MD simulation enables the study of time evolution 
of a large system by taking many small successive time steps 
under atomic forces determined by a set of parameterized 
interaction functions (force field), including bonded interac-
tions (bonds, angles, and dihedral angles), non-bonded van 
der Waals interactions, and electrostatic interactions based or 
net atomic charges. Due to the simple force field form the MD 
simulation may be performed for a sufficiently long simula-
tion time to give meaningful ensemble-averaged properties, 
even for a very large system involving over a hundred thou-
Rl R2 
163 163 
121 121 
167 167 
123 123 
225 310 
218 225 
310 218 
149 149 
159 159 
189 265 
265 140 
lar method has been successfully used by other researchers to 
increase thermo stability of an enzyme with no reduction in 
catalytic efficiency (Korkegian et a!. (2005) Science 308, 
857). The partial atomic charges for the non-standard residue 
atoms were calculated by using the standard RESP protocol 
implemented in the Antechamber module of the Amber7 (or 
8) program package (Case, 2002). The computational mod-
eling using the RosettaDesign program allowed prediction of 
a set of CocE mutations calculated as having lower energy 
and, therefore, increased thermostability (see e.g., Table 2). 
For this example, computation considered only possible 
30 mutations on the amino acid residues having a distance of 
between 6-25 A from the cocaine substrate molecule. 
Identified single mutation CocE polypeptides calculated to 
stabilize CocE by about 2.1 to about 4.5 kcal/mol included: 
L163V (SEQ ID NO: 3); V121D (SEQ ID NO: 4); S167A 
35 (SEQ ID NO: 5); Q123E (SEQ ID NO: 6); V225I (SEQ ID 
NO: 7); I218L (SEQ ID NO: 8); A310D (SEQ ID NO: 9); 
A149S (SEQ ID NO: 10); S159A (SEQ ID NO: 11); S265A 
(SEQ ID NO: 12); S56G (SEQ ID NO: 13); W220A (SEQ ID 
NO: 14);T122A(SEQIDNO: 15);S140A(SEQIDNO: 16); 
40 F189L(SEQIDNO: 17);A193D(SEQIDNO: 18);T254R 
(SEQ ID NO: 19); N42V (SEQ ID NO: 20); V262L (SEQ ID 
NO: 21); L508G (SEQ ID NO: 22); Y152H (SEQ ID NO: 23); 
V160A (SEQ ID NO: 24); T172R (SEQ ID NO: 25); Y532F 
(SEQ ID NO: 26); T74S (SEQ ID NO: 27); W285T (SEQ ID 
45 NO: 28); L146P (SEQ ID NO: 29); D533S (SEQ ID NO: 30); 
A194R (SEQ ID NO: 31); G173Q (SEQ ID NO: 32); C477T 
(SEQ ID NO: 33); K531A (SEQ ID NO: 34); R41I (SEQ ID 
NO: 35); L119A (SEQ ID NO: 36); K46A (SEQ ID NO: 37); 
and F84Y(SEQ ID NO: 38) 
TABLE2 
Summary of computational modeling using the RosettaDesign 
12rograrn with consensus a12:12roach 
Energy 
Consensus Change 
R3 R4 R5 R6 R7 R8 R9 RIO mutation (kcal/mol) 
163 163 163 163 163 163 163 163 L163V -4.5 
121 121 121 121 121 121 121 121 V121D -3.9 
167 167 167 167 167 167 167 167 S167A -3.9 
123 123 123 123 123 123 123 123 Q123E -3.8 
310 225 225 225 225 310 225 218 V2251 -3.6 
218 218 218 218 218 225 218 225 1218L -3.5 
225 310 310 310 310 218 310 152 A310D -3.4 
152 149 149 149 149 149 149 310 A149S -3.3 
140 159 159 159 159 159 159 149 S159A -3.3 
149 265 265 265 265 265 189 265 S265A -3.3 
265 56 56 56 56 220 265 159 S56G -3.2 
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TABLE 2-continued 
Summary of computational modeling using the RosettaDesign 
program with consensus approach 
Energy 
Consensus Change 
Rl R2 R3 R4 R5 R6 R7 R8 R9 RIO mutation (kcal/mol) 
56 220 159 220 220 220 220 122 56 220 W220A -3.2 
220 122 220 122 122 122 122 140 220 56 T122A -3.1 
122 189 122 140 140 140 140 189 122 122 S140A -3.1 
140 193 189 189 189 189 189 193 140 140 F189L -3.1 
254 42 193 193 193 193 193 42 254 189 A193D -3.1 
262 262 42 254 254 254 254 254 42 193 T254R -3.1 
508 508 262 42 42 42 42 262 262 262 N42V -3.0 
152 152 508 262 262 262 262 508 508 508 V262L -3.0 
160 160 198 508 508 508 508 152 152 198 L508G -2.9 
74 198 160 152 152 152 152 160 160 254 Y152H -2.9 
172 74 74 160 160 160 160 198 198 74 V160A -2.8 
193 172 172 198 198 74 198 74 172 160 T172R -2.8 
532 532 532 532 74 172 74 172 74 172 Y532F -2.7 
146 146 56 74 172 532 172 532 193 532 T74S -2.7 
285 285 285 172 532 146 532 146 532 285 W285T -2.6 
533 290 146 285 146 285 146 285 285 290 L146P -2.6 
173 254 533 146 285 533 285 533 146 146 
194 533 173 533 533 173 533 173 533 533 D533S -2.5 
477 56 194 173 194 194 173 194 173 173 A194R -2.4 
531 173 200 194 200 290 194 200 194 194 G173Q -2.4 
42 194 477 200 290 477 200 290 200 200 C477T -2.4 
119 200 531 290 477 531 477 477 290 477 K531A -2.4 
200 477 305 477 531 200 531 531 477 531 
41 531 41 41 41 41 41 41 531 42 R411 -2.2 
46 41 119 119 119 119 119 119 41 119 L119A -2.2 
84 119 46 46 173 46 46 46 119 41 K46A -2.1 
305 46 84 84 46 84 84 56 46 46 F84Y -2.1 
478 57 158 478 84 478 305 84 84 57 
57 84 307 57 478 57 478 307 478 84 
87 478 478 142 57 87 57 478 57 158 
142 87 57 263 87 142 87 57 142 478 
263 142 142 307 142 263 142 142 263 142 
307 263 263 78 263 307 263 263 307 263 
78 307 78 257 307 78 307 78 78 78 
257 78 257 531 48 257 78 257 257 257 
290 257 290 49 78 49 257 49 49 49 
291 201 49 201 257 305 201 201 201 201 
49 49 201 305 45 291 290 412 305 307 
176 291 291 412 49 176 291 291 412 291 
45 305 412 291 201 45 49 176 291 176 
54 176 176 176 305 54 176 45 45 305 
406 45 254 45 291 406 45 413 176 45 
50 54 45 413 176 50 54 54 413 54 
406 54 54 54 406 305 54 406 
50 413 50 406 50 406 406 50 
406 406 50 50 50 
50 
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Example 4 
50 
well as an additional Sac II restriction enzyme site for easy 
detection of the mutated gene. Primer pairs CocE 20-5'F-Nde 
Kinetic Parameters ofT172R and S159A Mutant 
CocE 
Wild-type CocE and the T172R and S159A mutant CocE 
polypeptides were tested for catalytic efficiency. 
Site directed mutagenesis (QuickChange™, Invitrogen) of 
CocE was performed to generate the S 159A (SEQ ID NO: 11) 
mutant CocE polypeptide. Cloning and expression tech-
niques used to produce the S159A were the same as in 
Example 1, except as indicated otherwise. The CocE gene 
was amplified through Polymerase Chain Reaction (PCR) in 
the presence of primers that contain the specific mutation 
required (Integrated DNA Technologies, Inc.). The specific 
mutation was subcloned back into the expression plasmid and 
the nucleotide sequence of these plasmids determined to 
verifY the presence of the mutation. 
Mutant T172R was generated by overlapping PCR using 5' 
and 3' primers containing the specific T172R mutation, as 
I (5' GATATACATATGGTGGACGGGAATTAC 3') and 
T172R-3'R (5' CAGACCTCGACGTGATGAGCCCGCG-
GCCTATGAGAGCTGACCAGC 3') as well as CocE-1800-
3'R (5' GTGGTGCTCGAGTCGCTTGATAATCG 3') and 
55 T172R-5'F (5' GCTGGTCAGCTCTCATAGG 
CCGCGGGCTCATCACGTCGAGGTCTG 3') were PCR-
amplified using the high-fidelity Pfu enzyme (Stratagene) 
with an annealing temperature of55° C. Resultant PCR prod-
ucts were combined and re-amplified, generating a full-
60 length CocE gene encoding the T172R mutation. The gene 
was digested with N de I and Xho I; subcloned into the expres-
sion vector, and sequenced in its entirety to verifY both the 
presence of the mutation and the absence of additional PCR-
copy error mutations. 
65 Plasmids containing the mutations were transformed into 
E. coli BL21 cells and IPTG-induced enzyme was purified on 
Ni-Agarose. Expressed proteins were then tested for enzy-
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matic activity and for thermostability at 3 7° C. Enzyme activ-
Vmax 
Km 
30 
TABLE3 
Kinetic parameters for T172R. S 159A, and wt CocE. 
S159A 
(40min 
S159A @ 37° C.) T172R 
876.6 130.7 1466 
43.65 15.69 88.20 
T172R 
(40min@ 
37° C.) 
1267 
78.80 
Example 5 
wt 
CocE 
1264 
71.81 
wtCocE 
(40min@ 
37° C.) 
94.06 
12.30 
In Vivo Wild-Type CocE Prevention of Cocaine 
Lethality in Rats 
ity was measured using the spectrophotometric assay as 
described in Example 1. Thermo stability was also tested via 
the spectrophotometric assay by pre-incubation of both wild-
type and mutants at 3 7° C. for various times. Additionally, the 
nature of the thermo-instability of both the wild-type and 
T172R mutant was analyzed by polyacrylamide gel electro-
phoresis under denaturing and non-denaturing conditions. 
Briefly, mutant and wild-type enzyme at 0.1 mg/ml were 10 
incubated at 37° C. for various time-points, cooled to 4 o C., 
mixed with SDS-loading dye containing-mercaptoethanol 
and run on 10% SDS-PAGE gels (denaturing conditions) or 
run on native 10% polyacrylamide gels (non -denaturing con- 15 
ditions) at 4 o C. Gels were fixed with 10% methanol, 7% 
acetic acid for 30 minutes, and then stained with Sypro-Ruby 
protein gel stain (Molecular Probes, Invitrogen) for 3 hours. 
Protein staining was visualized under UV-light using an 
Alphaimager™ 3400 (Alpha Innotech). Finally, the exact 
melting temperature of both the wild-type and T172R mutant 
were determined by circular dichroism using a JASC0-810 
spectropolarimeter driven by a JASCO V500/FP-7 50 analysis 
program for Windows. The CD spectra were measured in 
millidegrees and normalized against PBS buffer. 
To determine CocE's esteratic activity in vivo, a rodent 
model of acute cocaine toxicity was implemented. When 
treated with high doses of cocaine, rats first exhibit convul-
20 sions followed by cessation of respiration and movement. The 
lowest toxic dose of cocaine, when administered intraperito-
neally, will produce fatality within 15 minutes of treatment. 
Protection against cocaine-induced lethality by wild-type 
CocE was determined and compared to the protective effects 
Results from the spectrophotometric assay showed that 
T172R had an increased Vmax and Km at room temperature 
25 of human BChE. The esteratic activity of CocE was estab-
lished by assessing the activity of two mutant enzymes, each 
lacking one of three amino acids in the active site. Addition-
ally, activity of a modified wild-type enzyme by a covalent 
and a greatly increased Vmax and Km at 37° C. as compared 30 
to wild-type CocE (see e.g., Table 3; FIG. 5). In fact, the 
modification ofSer17 within the active site, by phenylmethyl 
sulphonate fluoride (PMSF) was determined. Esteratic deg-
radation of cocaine was shown to be the mechanism of 
CocE's protective effects by verifying if the enzyme pro-
tected against toxicity induced by WIN 35065-2 (Madras et 
a!. (1989) J Pharmacal Exp Ther 251, 13-141), a cocaine 
T172R Vmax and Km at 37° C. was comparable to the Vmax 
and Km of wild-type CocE at room temperature. The S159A 
mutant CocE showed a slightly increased Vmax and Km at 
3 7° C., but a decreased V max and Km at room temperature, as 
compared to wild-type CocE. Electrophoresis under denatur-
ing conditions (FIG. 6a) indicated a single protein band for 
both the wild-type and T172R of approximately 65000 Da, 
35 analog which lacks the ester bridge at the proposed site of 
enzymatic hydrolysis. 
regardless of incubation temperature, indicating the pro- 40 
teo lytic degradation does not adequately describe the mecha-
nismforthermoinstability. The non-denaturing gels (FIG. 6b) 
showed a single protein band for the wild-type enzyme prior 
to incubation at 37° C., however upon incubation at 37° C., 45 
higher molecular weight species are seen to appear as the 
Male Sprague-Dawley rats (300 grams) (Harlan Sprague 
Dawley, Indianapolis, Ind.) were housed three animals per 
cage. Following surgical implantation of a jugular catheter, 
all rats were individually housed until termination of the 
experiment. Rats were maintained on a 12-h light/dark cycle, 
with lights turned on at 7:30 a.m. and food and water were 
available ad libitum. After rats were anesthetized with ket-
amine hydrochloride (100 mg/kg, i.p.) and xylazine (10 
mg/kg, i.p.), intravenous catheters (Micro-renethane tubing, 
15 em, MRE-040, Braintree Scientific Inc., Braintree, Mass.) 
were implanted into the right jugular vein. Approximately 3 
em of the catheter was inserted into the vein; the remaining 
tubing was passed subcutaneously to the back, where it exited 
original band fades. These putative protein aggregates can 
also be observed for the T172R mutant, however the time to 
aggregation upon 37° C. incubation is longer, and in this 
procedure the T172R mutant was approximated to have a 8x 
longer half-life at 3 7° C. than the wildtype. Analysis of the 
protein melting temperature by circular dichrosim (FIG. 7) 
indicated temperature sensitive changes in protein tertiary 
structure were occurring in the near-UV range of the spec-
trum (between 260 nm and 320 nm). Curve-fitting of tem-
perature-sensitive changes in this region of the spectrum indi-
cated the wild-type CocE has a melting temperature of36.15° 
50 from an incision made between the shoulder blades. The 
exposed tubing was capped with a 1 em piece of stainless steel 
(0.28 diameter, Small Parts Inc., Miami, Fla.). Catheters were 
flushed daily with 0.5 ml of heparinized saline (50 U/ml) to 
maintain catheter patency. Following surgery, rats were 
55 allowed one week to recover. Each rat was used for a single 
experiment, and all experimental groups consisted of 6-8 rats. 
C., with detectable denaturation beginning at approximately 
30° C. The T172R mutant was determined to have a melting 60 
temperature of 41.43° C., with detectable denaturation begin-
ning at approximately 28° C. Thus the single amino acid 
change from Tyrosine to Arginine at Amino acid 172, with an 
estimated 2.8 kCa/mol increase in thermostability, was deter- 65 
mined to have a full 5 degrees increased melting temperature 
compared to the wild-type CocE. 
To determine the lowest effective dose of CocE that 
blocked cocaine-induced convulsions and death, 0.1, 0.3 2, or 
1.0 mg CocE or vehicle (phosphate buffered saline, PBS) was 
administered intravenously one minute after 180 mg/kg 
cocaine (i.p.). To determine the catalytic limits of CocE, 
increasing doses of cocaine were administered (1 00, 560, 
1000 mg/kg, i.p.) one minute prior to 1.0 mg CocE (i.v.). 
Mutants and PMSF -blocked CocE were administered (1 mg, 
i.v.) one minute before 180 mg/kg cocaine (i.p.). CocE (1.0 
mg, i.v.) was also administered one minute after the lowest 
dose ofWIN-35065-2 (560 mg/kg, i.p.). CocE (1.0 mg, i.v.) 
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was given before and after cocaine (100 mg/kg, i.p.) to deter-
mine the in vivo half-life of the esterase. All intravenous 
injections were followed by a heparinized saline flush (0.5 
ml). After treatment, rats were observed for convulsion; and 
death. Number of convulsant episodes, duration of each epi-
sode, and type of convulsion were recorded. Death was 
defined as cessation of observed movement and respiration. 
Percent of animals in each experimental group exhibiting 
convulsions and lethality were calculated. Percent standard 
error mean was then calculated for each data point. 10 
Results showed that, in the rodent model of acute toxicity, 
cocaine dose-dependently induced convulsions and death in 
rats; death was observed in less than 15 minutes after admin-
istration in 100% of animals given 100 mg/kg cocaine (see 15 
e.g., FIG. 9). CocE (1.0 mg) infused after cocaine adminis-
tration produced a ten-fold shift in the cocaine-toxicity dose 
effect curve (see e.g., FIG. 9), such that 1000 mg/kg cocaine 
was required to surmount the protective, catalytic properties 
of CocE. This treatment regimen closely resembles human 20 
toxicity situations, where the antidote to overdose is given 
only after cocaine has been ingested, inhaled, or injected. 
Wild-type CocE showed superior catalytic efficiency over 
human BChE. Given one minute before 180 mg/kg cocaine, 1 
mg CocE offered 100% protection against cocaine-induced 25 
lethality (see e.g., FIG.10), while a 10-timesmolarequivalent 
dose ofhuman BChE (13 mg) offered no protection, similar to 
a ten-fold lower dose ofCocE (0.1 mg) (see e.g., FIG. 10). 
Both mutations of CocE (Ser117 Ala or Tyr44Phe) lacked 
in vivo activity and, therefore, had no protective effects (FIG. 30 
llb). Furthermore, PMSF-treated enzyme also eliminated 
CocE's protective effect against cocaine (FIG. llb). Addi-
tionally, the lethal effect of the nonhydrolyzable cocaine ana-
log, WIN35065-2, wasnotovercomebytreatmentwithCocE 35 (FIG. 12). Based upon in vivo protection studies performed 
with catalytically inactivated preparations of the enzyme 
(PMSF-treated and CocE inactive mutants), it is clear that the 
protective effects of the enzyme are due to its ability to hydro-
lyze cocaine. Taken together, these data comply with in vitro 40 
assessments of CocE's esteratic activity and confirm the 
enzyme's mechanism of protection against cocaine-induced 
lethality in vivo. 
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!ism. Tissue extractions were performed and levels of cocaine 
and internal standard were quantified by HPLC with tandem 
mass spectrometry. 
For time-dependent inactivation of CocE in vitro, purified 
CocE enzyme (at 250 ng/ml) was incubated in assay buffer in 
the absence of cocaine at 37° C. for various times. Following 
incubation at 37° C. the samples were placed on ice. To assess 
the effect of temperature on CocE activity, samples were 
incubated with (-) cocaine at various concentrations as indi-
cated at a final enzyme concentration of 125 ng/ml. The rate 
of decay of (-)-cocaine atA240 was measured on a multiplate 
reader. The data were fitted to a single exponential decay 
using Kaleidagraph™ (Synergy software) yielding a t,n of 
13.2. 
Wild-type CocE was found to have time-dependent protec-
tive effects; 100% of rats were saved when treated with CocE 
(1 mg) 1 minute before cocaine, while only 66% and 32% of 
rats survived when treated with CocE 30 and 1 minutes before 
cocaine, respectively (see e.g., FIG. 14). CocE's protective 
effects were eliminated when rats were treated 100 min prior 
to cocaine. This time-dependent effect is most likely due to 
the thermal deactivation of the enzyme in vivo. In rat plasma, 
CocE was found to have a remarkably short half-life (about 10 
minutes, FIG. 13), most likely due to sensitivity to changes in 
pH and temperature. Additionally, preliminary in vitro data 
with the purified enzyme suggests that CocE undergoes a 
temperature-dependent inactivation with a t112 of approxi-
mately 15 min at 37° C. 
Given these data, it can be approximated that a 1 mg of 
CocE dose administered 30 minutes prior to cocaine, will 
decay approximately 3 half-lives, leaving 0.25 mg of wild-
type enzyme in the general circulation when cocaine is 
administered. 
Previous studies have suggested that lethal blood concen-
trations of cocaine in the rat vary between 50-128 f.LM (Mets 
Band Virag L (1995)AnesthAnalg 81, 1033-1038; Mets eta!. 
(1999) Life Sci 65, 1317-1328), and peak plasma levels of 
cocaine occur about 13 minutes after an intraperitoneal injec-
tion (Sun eta!. (2002) J Pharmacal Exp Ther 302, 710-716). 
Based on reported kinetics of intraperitoneal cocaine admin-
istration (Sun eta!. (2002) J Pharmacal Exp Ther 302, 710-
716), it is estimated that 100 and 320 mg/kg cocaine yield 
peak cocaine blood concentration of 35 f.LM and 113 f.LM, 
Example 6 
Time-Dependent Effects ofWild-Type CocE 
The effects of administering wild-type CocE prior to 
cocaine dosage was examine. The rat toxicity model was as 
described in Example 5. Wild-type CocE was adminstered 
100, 30, 10, 3, and 1 minute before and 1 and 6 minutes after 
cocaine administration. Compound extractions from human 
plasma samples were performed in 100% acetronitrile (3x 
volume), incubated for approximately 15 min, centrifuged at 
13,000 rpm for 4.5 min, and the resulting supemantant was 
collected. The extracts were concentrated on a Savant Speed 
Vac (ThermoE!ectron Corp., Franklin, Mass.) to remove the 
acetonitrile. Extracted samples were reconstituted in water 
and further diluted 10-1000 times. 
45 respectively. Lethal concentrations of cocaine are of a similar 
magnitude in humans (20-200 f.LM) (Finkle B Sand McClos-
key K L (1978) J Forensic Sci 23, 173-189; Wetli and Wright 
(1979) JAm MedAssoc 241, 2519-2522). As 1 mg of wild-
type CocE saved rats treated with these doses of cocaine (FIG. 
Human plasma samples were spiked with 300 f.LM cocaine 
and maintained at 3 7° C. One aliquot of plasma was sampled 
prior to the addition of cocaine esterase or esterase vehicle, 
and another aliquots was collected 1 min following esterase 
administration. Plasma aliquots were mixed immediately 
with the internal standard (cocaine-D3 ) and a saturated 
sodium fluoride solution to prevent further cocaine metabo-
50 9), it can be justifiably predicted that the enzyme would 
protect against cocaine-toxicity in the human. Furthermore, 
cocaine levels measured using high performance liquid chro-
matography tandem mass spectrometry in human plasma 
spiked with 300 f.LM cocaine, a concentration that exceeds 
55 reported toxic levels of cocaine, and then treated with CocE (a 
molar equivalent of our in vivo 1.0 mg dose), reduced the 
cocaine concentration to approximately 2 f.LM in less than a 
minute (FIG. 10). 
Protection against an LD50 dose of cocaine in rats requires 
60 a 10 mg/kg treatment ofBChE (Lynch eta!. (1997) Toxicol 
Appl Pharmacol145, 363-371), assuming that the enzyme is 
distributed similarly in the human, a 70 kg individual would 
require a 700 mg dose of exogenous BChE to protect against 
an overdose. Furthermore, there is no evidence that BChE can 
65 act to reverse cocaine-toxicity when administered after 
cocaine, a necessary characteristic of an antidote for cocaine 
toxicity. 
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It is thus demonstrated that a dose of 1 mg wild-type CocE 
in a 300 gram rat is sufficient to protect against a dose of 
cocaine that exceeds the LD100 (FIG. 9). Additionally, the 
enzyme given both before, and more importantly, up to 6 
minutes after the LD 100 dose of cocaine, provided protection 
from toxicity (FIG. 14). CocE metabolized cocaine concen-
trations in serum by 150-fold in less than one minute (FIG. 
15). 
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For intravenous catheterization, Male NIH Swiss mice are 
anesthetized with ketamine 100 mg/kg and xylazine 10 
mg/kg co-administered i.p. When mice are no longer respon-
sive to paw pressure, the neck is shaved and prepped by 
alternating Betadine and alcohol wipes. Under clean condi-
tions, a right transverse neck incision is made and the external 
jugular vein is isolated. A catheter is inserted into the vein 
with the aid of a dissecting microscope to the level of the right 
Given these data, it is predicted that a 250 mg of CocE 
administered to a 70 kg human after toxic cocaine ingestion 10 
would rescue the individual from certain death. The above 
atrium, and is secured in the vein with nylon, 4-0 sutures and 
tissue adhesive, 3M Vetbond (3M Animal Care Products, St. 
Paul, Minn.). The catheters are a short length ofTygon tubing 
demonstrates that wild-type CocE is an efficient anti-cocaine 
molecule but that the short activity time of the enzyme under 
physiological conditions limits it therapeutic value. Such 
results point to the importance of extending the thermo stabil-
ity of the wild-type CocE. 
Example 7 
In Vivo T172R Mutant CocE Prevention of Cocaine 
Lethality in Rats 
The hydrolytic activity of wild-type CocE and T172R 
mutant CocE was characterized and confirmed in vivo by 
assessing its ability to prevent cocaine-induced lethality in 
rats. 
with an inner diameter of0.010 in. and an outer diameter of 
0.030 in. (Small Parts, Inc., Miami Lakes, Fla.). A small 
incision is made in the middle of the animal's back, and a 
15 trocar inserted subcutaneously to exit at the ventral incision 
site. The catheter is then pulled through the trocar and brought 
out the animal's back where it is held in place with nylon 
suture material and the tissue adhesive. A short piece of steel 
wire with a diameter of 0.011 in. (Small Parts, Inc., Miami 
20 Lakes, Fla.) is inserted into the end of the catheter. The ventral 
incision is closed with 4-0 Vicryl suture material and the 
mouse placed under a heat lamp for recovery. Approximately 
an hour later, the mouse is returned to its home cage. 
Mice that survived a first administration of the combination 
25 of 0.32 mg CocE and 320 mg/kg cocaine were given this 
combination again, 14 days following the initial administra-
tion. All of the mice survived this second administration. All 
mice also survived a third administration 21 days following 
Animal treatment was as described in Example 5. Increas-
ing doses of cocaine were administered (i.p.) to rats, and one 
minute after, wild-type CocE (0.32 mg), mutant CocE T172R 
(0.32 mg), or vehicle was administered intravenously. All 30 
intravenous injections were followed by a heparinized flush 
(0.5 ml). After treatment, rats were observed for death. Time 
until death was recorded for the 1 g/kg cocaine dosage. Wild-
type and T172R CocE (0.32 mg) was administered at various 
times preceding (1, 10, 30, and 60 minutes) administration of 35 
320 mg/kp i.p. of cocaine, with rats then monitored for death. 
the first dose combination. The effectiveness of repeated 
administration suggests that a strong immune response is not 
being mounted to CocE in this preparation, perhaps because 
of its rapid clearance. 
Results showed that a dramatic shift to the right in the 
potency of cocaine in producing death was afforded by both 
0.32 and 1.0 mg/kg cocaine (see e.g., FIG.18). The latency to 
death was markedly extended by CocE: following 180 mg/kg 
i.p. cocaine, mice typically died in about 3 min. After a dose 
of 1.0 gm/kg cocaine plus 1.0 mg of CocE, death occurred at 
28 minutes on average. Data was also examined for the ability 
ofhBChE to block the toxicity of cocaine. At a dose of 1 mg, 
hBChE produced a slight increase in the dose of cocaine 
necessary to kill the mice (see e.g., FIG. 18). This enzyme is 
markedly less effective than CocE. Although larger doses of 
cocaine were necessary to kill the mice following adminis-
Results demonstrate the ability of intravenous CocE and, 
especially, mutant CocE to reverse or prevent the lethal 
effects produced by cocaine. Wild-type CocE adminstered 
one minute after cocaine administration prevented lethality at 40 
cocaine dosages that killed control rats and 100% lethality did 
not occur until cocaine dosages of 1 g/kg (see e.g., FIG. 16). 
The T172R mutant CocE treated rats were able to tolerate 
even higher dosages, with the 1 g/kg of cocaine resulting in 
only about 70% lethality. And the prophylactic effects of 
T172R mutant CocE was longer lasting than the wild-type 
CocE (see e.g., FIG. 17). 
45 tration ofhBChE, the time to death was not modified by this 
enzyme. 
Example 8 
In Vivo Repeated CocE Dose in Mice 
Additional studies were done on the effect of CocE on 
toxicity in the mouse, particularly with respect to repeated 
doses. 
The animal toxicity model was similar to that described 
previously, except as described. Male NIH Swiss mice were 
used. For tail intravenous injection, mice are placed in a small 
restraint chamber that exposes their tail. A heat lamp with an 
infrared, 250 w bulb is placed about 4 inches from the tail, and 
left for a couple of minutes. The tail is then cleansed with an 
alcohol wipe and a 30 G lf2 precision glide needle (Fisher 
Scientific), is inserted into one of the side veins for infusion. 
To verifY whether the needle is in the vein a small amount of 
drug is infused, if in the correct location the solution should 
infuse easily without any indication of an incorrect subcuta-
neous location, which appears white at the site of injection. 
50 
Example 9 
In Vivo Half-Life and Biodistribution Tests 
The in vivo half-life and biodistribution of the mutant CocE 
polypeptides are examined in BALB/c mice. In brief, 125I is 
labeled to the tyrosine residues of mutant CocE by using the 
55 well-established chloramine-T iodination method (Hunter, W 
M and Greenwood, F C (1962) Nature 194, 495-496). 
BALB/c mice are injected via their tail veins with 0.1 mL of 
either 0.5 f.l.Ci 125I-labeled mutant CocE or the mutant CocE-
PEG conjugates. Each experimental group consists of 24 
60 mice. Three mice are sacrificed by cervical dislocation at the 
15-,30-, 90-minute, 3-, 12-,24-,48-, and 72-hourtime inter-
vals following the drug injection. Blood samples as well as 
tissue samples of liver, lung, heart, kidney, and spleen are 
collected, weighed, and measured for radioactivity using a 
65 gamma counter. The blood samples are also centrifuged, and 
the supernatants will be collected and counted for estimation 
of plasma-associated radio labels. The ratio of the peak to that 
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of the internal standard is used as the assay parameter. PK 
parameters are calculated by using the KINFT (Kaltenbach, 
36 
M Land Vistelle, R (1994) Anticancer Research 14, 2375-
2377) nonlinear least-squares computer program by fitting 
the plasma radioactivity data to a biexponential equation 5 
(Gibaldi, M. and Perrier, D. (1982) Pharmacokinetics): 
compared to the positive control animals immunized by CocE 
plus IFA. Serum collected from animals immunized once 
with CocE/IFA demonstrated high titer of 105 , while serum 
from animals given an additional boost were had a higher titer 
of 106 (3 mice/group). The serum collected from these ani-
mals will serve as positive controls for all subsequent titering 
experiments. 
TABLE4 Where A(t)=% ID/mL plasma and ID=injected dose. k2 
will be used to calculate the first-order elimination time t112 . 10 
The area under the curve (AU C) of the plasma concentration-
time curve, the steady-state volume of distribution (V ss ), total 
plasma clearance (CI), and the mean residence time (MRT) 
are calculated from AD A2 , k 1 , k2 , and the body weight (kg) of 
the mouse as described by Gibaldi and Perrier, 1982). The 
organ permeability-surface area (PS) product is calculated as: 
CocE titers of immunized mice 
Group 
15 Positive 1 (n ~ 3) 2 weeks 
Positive 2 (n ~ 3) 3 weeks 
Protocol 
Immunized (IFA/IP) 
Immunized/Boost 
(IFA/IP) 
Titer (log10 
dilution +1- SE 
PS~[V r V JCp(60min/AUCco-6omin) Challenged and Treated (3x) CocE given with cocaine Challenged and Treated (4x) CocE given with cocaine 
3.33 +1- 0.333 
3.5 +1- 0.5 
Where CPc6 omin) is the terminal plasma concentration 
(dpm/f.LL) at 60 min after injection, V dis the tissue volume of 20 
distribution determined from the ratio of disintegrations per 
minute per gram of tissue to Cpc6omin)' and V o is the organ 
plasma volume. The organ delivery of the samples is deter-
minedas: 
Example 11 
CocE Pegylation 
% ID/g~PSxAUCco-60min) 
Where % ID/g is the percent injected dose taken up by 
gram of organ. 
Example 10 
Immunology 
CocE can be used in incomplete Freund's adjuvant (IFA)to 
immunize mice (see Table 4). A direct ELISA specific for 
CocE antibodies was set up by a standard protocol. CocE was 
used (1 ug/ml) to coat a 96-well micro-titer plate using a 
borate buffered saline (1.5 M NaCl, 0.5 M H3B03, 1.0 M 
NaOH) to resuspend the cocaine esterase (50 uL/well). The 
coating plates was left overnight at 4 C. The coating buffer 
was removed the following morning and the plates blocked 
with 2% normal goat serum in PBS for 1 hr at 37 C and 
washed 3 times. Serum from the various groups of mice was 
serially diluted in 50 flL of PBS in the wells in a range of 102 
to 1 0' and run in duplicate. The plates were covered and 
incubated for 30 minutes at 37 C. Subsequently, the plates 
were washed 3 times and 50 fJ.Liwell of Goat anti-mouse IgG 
peroxidase labeled antibody diluted 1:400. The plates were 
then washed 3 times and 100 f.LL peroxidase substrate solution 
(OPD dissolved in citratelphosphate buffer) was added to 
each well. After a 5-10 minute incubation (based upon color 
development in the positive controls) the reaction was 
stopped using 3M H2S04 (50 fJ.Liwell). The plates were read 
at 490 nm and titer determined by the highest dilution that 
showed increases over background absorbance. Positive con-
trols were derived by immunizing Balb/c mice with 100 flg in 
100 f.LL of Cocaine esterase emulsified in incomplete Fre-
und's adjuvant (IPA) by intraperitoneal (IP) injection. In 
Positive 1 group the serum was isolated from 2 week immu-
nized mice. In Positive 2 group immunized mice were 
boosted using 100 flg in 100 f.LL by IP injection at 2 weeks 
post-primary immunization and the serum collected after an 
additional week (3 week post-primary). 
High titers were derived from the two positive control 
groups immunized with CocE, 105 and 106 , respectively. The 
antibody titers from animals given CocE i.v. during cocaine 
challenges demonstrated detectable but relatively low titers 
25 
Conjugation of one to two PEG polymers per enzyme 
molecule is generally sufficient to yield the desired protective 
effects (Avramis eta!. (2002) Blood 99, 1986-1994). Because 
each wild type CocE molecule is reported to contain 8 lysine 
30 residues, with none in the active site but only 2 being close to 
the active site (Turner eta!. (2002) Biochemistry 41, 12297-
12307), targeting lysine for pegylation is unlikely to inacti-
vate the enzyme. The mutant CocE is mixed with various 
monomethoxy-PEG (m-PEG) polymers (MW ranging from 
35 3-12 KDa); all contain an activated N-end functional hydrox-
ysucciniyl ester group (mPEG-NHS; from Shear Water Inc., 
Birmingham, Ala.). PEGwithamolecularweight of5.5 KDa 
will be first attempted, because the inventors' results and 
those of other investigators (see e.g., Veronese, F M and 
40 Harris, J M (2002) Advanced Drug Delivery Reviews 54, 
453-456; Avramis eta!. (2002) Blood 99, 1986-1994) dem-
onstrated that this molecular weight yields the beneficial pro-
tection. Different molar ratios of [NH2 ] :[ mPEG] (the former 
is calculated based on the total moles of lysine residues of 
45 mutant CocE) ranging from 1:2 to 1:10 are tested to obtain 
optimal conditions. Conjugation proceeds for about 40 min-
utes at 4 o C. with gentle agitation. The reaction products are 
then purified by ultrafiltration (MWCO 10,000) at 4° C. 
Activities of the pegylated mutant CecE products are deter-
50 mined by measuring the initial rates of cocaine hydrolysis 
using the previously established procedure (Turner et a!. 
(2002) Biochemistry 41, 12297-12307). In addition, 
MALDi-TO F mass spectraphotometry is performed on these 
products to analyze the degree of pegylation and their 
55 molecular weight. The pegylated products are stored at -40° 
C. and thawed immediately prior to their uses. 
Standard characterization, including determination of the 
optimal pH, temperature, ionic strength, as well as kinetic 
parameters (e.g. Km, Vm), of the mutant CocE-PEG conju-
60 gates are conducted in PBS. Furthermore, thermal stability of 
the pegylated products and their stability against proteolytic 
degradation are examined in the presence of human plasma or 
blood. In vivo functional tests of the mutant CocE-PEG prod-
ucts are conducted as described above. The in vivo half-life 
65 and biodistribution of the mutant CocE-PEG conjugates, as 
compared to free CocE are conducted as described above (see 
Example 9). 
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Statistical analysis is performed on the results obtained 
from the pegylation experiments. Random block two-way 
ANOVA with Dennett's post-test is performed on data sets 
with two variables using GraphPad (San Diego, Calif.) Prism 
for Windows and GraphPad Software. Paired t-test is per- 5 
formed for experiments with two conditions. 
Conjugation of mutant CocE to high molecular weight 
38 
12297-12307), suggesting that use of these free cysteine 
groups for conjugation is not likely to impair the catalytic 
activity of this enzyme (already performed mutation of each 
cysteine in wild-type CocE to a serine resulted in no dimuni-
tion of activity). The final LWMP-CocE products is then 
purified via a heparin column, and is stored by lyophilization. 
Encapsulation is achieved by incubating RBC with mutant 
CocE-LMWP for 30-60 minutes. Because PTD-mediated 
cell entry is temperature-independent (Schwarze eta!. (1999) 
(e. g., up to 60 KDa) branched PEG can also be performed (see 
e.g., Reddy et a!. (2002) Advanced Drug Delivery Reviews 
54, 571-586). 10 Science 285, 1569-1572), encapsulation is conducted at 4° C. 
to maximally preserve the functionality ofRBC. The process 
and extent of mutant CocE entrapment in RBC is monitored 
by confocal microscopy and flow cytometry analysis using 
Additionally, site specific PEGylation can be a viable alter-
native to reduce functional and structural heterogeneity. The 
removal of cysteine residues near the active site or incorpo-
ration of cysteine residues on the protein surface can serve as 
better PEGylation substrates (through maleimide coupling). 15 
Similarly, amine-coupling of PEG to CocE can be employed 
through, for example, the conservative substitution of argin-
ine residues for any of mutant CocE' s (nine lysines total in 
wild-type CocE, seven of which are surface lysines). 
Preliminary findings have shown that wild-type (WT) 20 
CocE was successfully linked with monomethoxy-PEG 
(m-PEG) polymars (MW: 5.5 KDa) containing an activated 
succinimidyl functional group at one end, using the proce-
dures described above. A high yield of the initial CocE activ-
ity (>70%) was recovered after the pegylation reaction. 25 
MALDI-TOF mass spectra revealed four primary peaks for 
the PEG-CocE products, indicating the presence of a hetero-
geneous mixture of the conjugates containing different num-
bers of the PEG chains (ranging from 1 to 4, respectively) (see 
e.g., FIG. 19). It has been suggested in the literature that 30 
conjugation of merely 1-2 PEG chains per protein molecule 
would be able to yield PEG-induced protective effects 
(Veronese, F M and Harris, J M (2002b) Advanced Drug 
Delivery Reviews 54, 457-606; Avramis eta! (2002) Blood 
99, 1986-1994). To this regard, the pegylation method 35 
employed here apparently satisfies such a requirement. 
Example 12 
FITC-labeled mutant CocE. The morphology of mutant 
CocE-entrapped RBC is also be examined by SEM. 
Basic characterization-including assessment of the func-
tionality of both RBC (e.g. oxygen-transfer activity) and 
mutant CocE (e.g. cocaine-hydrolyzing activity, kinetic prop-
erties such as Km, Vm, etc.), leakage of mutant CocE from 
RBC (i.e. by incubating mutant CocE-loaded RBC in buffer 
and then measuring enzyme activity in the supernatant), and 
stability of the entrapped mutant CocE against proteolytic 
degradation-is conducted either in buffer or in plasma. 
Results obtained for the RBC-encapsulated mutant CocE are 
compared with those obtained for the free enzyme. In vivo 
functional tests of the mutant CocE-encapsulated RBC are 
conducted as described above. 
Human RBC (from American Red Cross, Detroit, Mich.) 
are used for in vitro studies. For in vivo animal studies includ-
ing the functional tests and pharmacokinetic studies, how-
ever, autologous RBC from the same animal species are be 
used to avoid cell incompatibility and possible toxic effects. 
Circulation half-life (t112) of mutant CocE-entrapped RBC 
is determined by injecting 125I-labeled mutant CocE (i.e. 
prior to its loading into RBC) into mice, according to the same 
procedures described above. Each set of experiments consists 
of24 mice. Mice (3) are sacrificed at 3-, 6-, 12-, 24-hour and 
3-, 6-, 10-, and 15-day time intervals. Blood and tissue 
samples are collected, weighed, and measured for radioactiv-
RBC Encapsulation 40 ity. PK parameters including the elimination t112, as well as 
tissue distribution are calculated by using the KINFT pro-
gram as described above. Pharmacokinetic results obtained 
for the RBC-encapsulated mutant CocE are compared with 
those obtained for free mutant CocE. 
RBC encapsulation of CocE can be accomplished via a 
linked PTD peptide. LMWP is selected as the PTD peptide to 
ferry mutant CocE into RBC, because of its potency in trans-
locating proteins across cell membrane (Park et a!. (2005) 45 
FASEB Journal, in press) and its lack of toxicity (Chang eta!. 
(2001) AAPS Joumal3, Article #17, #18 and #19). To ensure 
that the encapsulated mutant CocE is permanently embedded 
in RBC, the linkage between CocE and LMWP can degrade 
automatically and rapidly once the mutant CocE-LMWP con- 50 
jugates enter RBC. A linker such as a disulfide (S-S) bond 
that will be degraded quickly inside the RBC due to the 
presence of elevated cytosolic glutathione and reductase 
activity (Trouet et a!. (1982) Proceeding of the National 
Academy of Science 79, 626-629), ensures that CocE will 55 
stay in the RBC. 
To produce mutant CocE-LMWP conjugates linked with 
S-S bonds, the amine group at theN-end ofLMWP (this is 
the only -NH2 group on LMWP) is first activated with 
SPDP, and the activated LMWP then mixed with mutant 60 
CocE in the presence of dithiothretol (DTT) to allow for the 
formation of the S-S bond with one of the (four in wild -type) 
free cysteine residues on mutant CocE (Turner et a!. (2002) 
Biochemistry 41, 12297-12307); according to a modified 
procedure previously developed (Liang et a!. (2000) AAPS 65 
Pharmaceutical Science 2, Article 7). CocE is stable when 
being stored in DTT (Turner eta!. (2002) Biochemistry 41, 
Statistical analysis is performed on the results obtained 
from the RBC encapsulation experiments. Random block 
two-way ANOVA with Dennett's post-test is performed on 
data sets with two variables using GraphPad (San Diego, 
Calif.) Prism for Windows and GraphPad Software. Paired 
t-test is performed for experiments with two conditions. 
To examine if the previously suggested could fulfill the 
latter two requirements, preliminary studies of PTD-medi-
ated RBC encapsulation were conducted using L-asparagi-
nase as a model enzyme. LMWVP, a PTD peptide previously 
developed in Dr. Yang's laboratory (Chang et a!. (2001) 
AAPS Journal 3, Article #17, #1, and #19) with proven, 
potent membrane-penetrating activity (Park et a!. (2005) 
FASEB Journal, in press), was linked to asparaginase using a 
procedure similar to that described above. The LMWP-AS-
Nase conjugates were then incubated with RBC (collected 
from DBA/2 mice) for 2 hrs at 4° C. For comparison, RBC-
Ghosts containing encapsulatedASNase were also prepared 
according to the previously established procedures (Updike 
eta!. (1976) Science 193, 681-683). Preliminary results dem-
onstrated that loading efficiency of the LMWP-mediated 
method was at least comparable to, if not better than, the 
conventional, osmosis-based cell rupturing technique. A 
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major advantage of the PTD-mediated method, however, is 
that it only requires a single step for processing; unlike the 
other cell entry methods that all require multiple steps of the 
loading and washing procedures. 
FIG. 20 presents scanning electron microscopy (SEM) 5 
images taken from samples of normal RBC, ASNase-loaded 
RBC-Ghost, and LMWP-ASNase-loaded RBC. As seen, 
while theASNase-loaded RBC from osmotic rupture/reseal-
ing method (i.e. RBC-Ghost) exhibited significant change in 
shape and morphology, the LMWP-ASNase-loaded RBC 10 
showed virtually indistinguishable shape and morphology 
(i.e. biconcave disk) from those of normal RBC. These find-
ings are in agreement with those reported by many other 
investigators that PTD-rnediated cell encapsulation does not 
cause any significant perturbation or alteration of the cell 15 
membrane (Dietz, G PH and Bahr, M (2004) Molecular Cell 
Neurosciences 27, 85-131; Schwarze eta!. (1999) Science 
285, 1569-1572; Suzuki eta!. (2002) Journal of Biological 
Chemistry 25, 2437-2443). 
To further evaluate these two RBC-encapsulation systems, 20 
preliminary clearance studies were carried out. The half-life 
of ASNase activity in plasma was evaluated after intravenous 
injection of: (1)ASNase-loadedRBC-Ghost, and(2) LMWP-
ASNase-loaded RBC. Each animal group consisted of 4 
DBA-2 mice, and each mouse was given 8 nnits of loaded 25 
ASNase activity. Blood samples were withdrawn at different 
time intervals from the tail vein, and the amonnt of ASNase 
activity in the whole blood was measured by direct Nessler-
ization of produced annnonia (Ho et a!. (1970) Journal of 
Biological Chemistry 245, 3708-15). Results demonstrated 30 
that there was almost a two-fold increase in the circulation 
half-life for the LMWP-ASNase-encapsulated RBC (t112 : 9.2 
days) compared to that (t112 : 5.9 days) fortheRBC-Ghost (see 
e.g., FIG. 21). It is currently unknown what the difference 
between the half-lives of the encapsulated RBC and the nor- 35 
mal, untreated RBC. Nonetheless, these results of 2-fold 
increase of t112 over RBC-Ghost demonstrate the merit of this 
approach, as it was reported in the literature that even by 
utilizing the RBC-Ghost encapsulation method, the in vivo 
ASNase activity had already been prolonged from 26 hours 40 
for the free ASNase to 29 days for the RBC-Ghost-encapsu-
lated ASNase (Kravtzoff et a!. (1996) European Journal of 
Clinical Pharmacology 49, 465-470): already a 10-fold 
increase. Hence, another 2-fold increase of this t 112 by the 
encapsulation method described herein is particularly effec- 45 
tive. 
To confirm that the RBC-encapsulatedASNase could still 
retain its original biological functions, anti-tumor effects by 
both the RBC-Ghost-ASNase and the RBC-ASNase were 
40 
anti-tumor treatment. Overall, these findings with the 
ASNase model enzyme demonstrated that the RBC-encapsu-
lated enzyme was still therapeutically active. It is noted that 
cocaine is more permeable across the RBC membrane than 
the asparaginase substrate. 
Thus, utilization of RBC-encapsulated CocE in treating 
cocaine-related conditions is an effective approach because 
cocaine readily crosses the RBC membrane (and actually 
somewhat concentrates in RBC) (Javaid eta!. (1978) Journal 
of Chromatography 15, 105-113 ), PTD-mediated encapsula-
tion does not alter the physical and/or chemical properties of 
the RBC, and the RBC-encapsulated enzyme functions as if 
free. 
Example 13 
Endotoxin Removal 
Endotoxin contamination of CocE mutants can be per-
formed in several ways. Ideally, endotoxin decontamination 
decreases the concentration to levels less than 10 EU/mg 
protein. Methods of decontamination include alternative ion-
exchange colunm chromatography conditions, size exclu-
sion, polyethyleneimine (PEl) and hydrophobic column 
chromatography, ultrafiltration and detergent extraction. An 
endotoxin detection system (PYROGENT 5000, Cambrex) is 
used to determine the endotoxin content of preparations. The 
assay is based on the anti-LPS factor from Limulus amebocyte 
lysate (LAL). The sensitivity of the assay is between 0.01 and 
100 EU/ml, well within the levels required. The spectropho-
tometric assay is designed in a 96-well microtiter-plate for-
mat. Fractionation of endotoxin and CocE and/or mutant 
CocE by the following procedures can be assayed for both 
endotoxin level and cocaine esterase activity. Cocaine 
esterase activity is measured utilizing a spectrophotometric 
assay that takes advantage of the intrinsic absorption of 
cocaine at 240 nm. Upon hydrolysis, the absorption spectra 
reveals a dramatic reduction in the 240 nm peak (Turner eta!. 
(2002) Biochemistry 41, 12297-12307). 
Anion Exchange Chromatography: Current conditions 
involve the use of fast performance liquid chromatography 
(FPLC) on a Q-Sepharose colunm at pH 8.0 for endotoxin 
decontamination. The buffer conditions (pH) can be opti-
mized to maximize the both the adsorption of CocE and/or 
mutant CocE and separation of endotoxin. Fluted fractions 
are assessed by activity measure of CocE or mutant CocE 
activity (spectroscopic assay of the hydrolysis of cocaine, 
absorption at 240 nm). Endotoxin levels are assessed using 
PYROGENT 5000 (above). 
Size Exclusion Chromatography and Ultrafiltration: 
Endotoxin can exist as monomeric forms (MW-1-2x104 ) or 
in micellar form (MW-4x106 to 1x106 ), depending on the 
buffer conditions. The presence of detergents such as cholate 
favors the monomeric form whereas divalent cations (e.g. 
examined on tumor-bearing mice. L5178Y mouse lymphoma 50 
cells were cultured, and to each DBA/2 mouse 7x105 cancer 
cells were injected intraperitonially. Five days after tumor 
implantation, mice with similar bodyweights were selected 
and divided into three groups: (1) Control group given saline 
only; (2) ASNase-loaded RBC-Ghost; and (3) LMWP-AS-
Nase-loaded RBC. Each group consisted of 5 mice, and each 
experimental mouse was given 0.1 mL of the drug-encapsu-
lated RBC (or Ghost). Results showed that the average sur-
vival times for the untreated control, ASNase-RBC-Ghost-
treated, and LMWP-ASNase-RBC-treated groups were 10.0, 
12.6, and 14.4 days, respectively (see e.g., FIG. 22). It should 
55 Ca2+) favor the micellar form (Hirayama, C and Sakata, M 
(2002) Journal of Chromatography B Analytical Technology 
Biomedical Life Science 781, 419-432). This property of 
endotoxin is used to separate the micellar (i.e. in the presence 
of divalent cations such as Mg2 + or Ca2+) from CocE and/or 
60 mutant CocE by Gel filtration chromatography using either a 
Sephadex 75 or Sephadex 200 (Pharmacia) colunm resin. 
Micellar endotoxin should not be retained on the colunm and 
should pass through the void whereas CocE and/or mutant 
be noted that although the survival time among the three 
groups differed by only about 2 days, the effects of the treat-
ment by the RBC-encapsulated ASNase was still quite dra-
matic; considering the fact that only 0.1 mL of the RBC 65 
suspension, which was equivalent to merely 5% of the total 
blood volume of the mouse, was given to each mouse for the 
CocE should elute as a monodispersed protein corresponding 
to a 65 kDa protein. Similarly, the capacity of ultrafiltration 
units to separate the micellar forms of endotoxin from CocE 
and/or mutant CocE will be assessed. Ultrafiltration units are 
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now available with molecular weight cutoffs of 3x105 to 
1 x 1 06 , well within the range required to retain micellar en dot-
oxin but not CocE itself. 
42 
Polyethyleneimine Chromatography: Mitzner eta!. (1993) 
and Morimoto eta!. (1985) have used PEl-immobilized on 
cellulose beads or on cellulose fiber, respectively to remove 
endotoxin from BSA preparations. PEl -chromatography col-
unm is a very weak anion exchanger that may in fact take 
advantage of some hydrophobic properties of endotoxin and 
thus preferentially adsorb it. Various PEl-silica bead prepa- 10 
rations are available from Sigma, depending on the bead size. 
While silica-based beads are more classically associated with 
HPLC applications we will pack colunms for lower pressure 
work and will select the 200 urn mesh sizes. 
tion of the CocE gene is performed on mutants found to 
produce active and soluble CocE at 37° C., and the amplifi-
cation products are subcloned into the pET-22B( +) plasmid 
for further characterization. As a prelude to CocE mutagen-
esis, it may be necessary to mutagenize the native Pseudomo-
nas strains in order to preselect for no temperature sensitivity 
at 37° C. when grown on cocaine hydrolysis products, and 
then demonstrate temperature sensitivity on cocaine at 37° C. 
after cloning in CocE. 
Example 15 
High Throughput Screening Method for 
Identification of Thermostable CocE Mutants 
Triton X-114 Extraction: Triton X-114 phase separation 15 
has been successfully used to separate endotoxin from albu-
min and catalase (Aida, Y and Pabst, M J (1990) J Immuno-
logical Methods 132, 191-195).AdiaandPabstreporta 1000-
fold decrease in endotoxin concentration following a single 
Triton X -114 extraction step. CocE and mutant CocE samples 20 
are incubated with equal volumes of Triton 114 and allowed 
Several high throughput screening methods for identifica-
tion of thermostable CocE variants were implemented. 
Because the wild-type enzyme is known to have thermal-
instability at temperatures above 30° C., after transformation 
into E. coli BL21 cells, colonies are subcultured and protein 
expression induced at 16° C. Expressed proteins are then 
to incubate first on ice and then at 3 7° C. for 15 minutes. The 
Triton X -114 phase that contains the endotoxin is removed by 
centrifugation. As noted earlier it has been demonstrated that 
CocE is considerably thermal labile, but may be protected 
somewhat by the presence of the substrate, cocaine. If incu-
bation ofCocE with Triton X-114 at 37° C. results in signifi-
cant CocE inactivation, the enzyme will be stabilized by 
including excess substrate during the extraction. 
Example 14 
Mutagenesis of the CocE Host Organism 
There exists several bacterial strains that exhibit tempera-
ture sensitive growth on cocaine esterase byproducts, includ-
ing several Pseudomonas strains, and these organisms can be 
adapted for temperature sensitive growth on cocaine by addi-
tion of the CocE gene encoded within suitable plasmid vec-
tors. For example, the CocE gene was originally sequenced 
from Rhodococcus MB 1 by subcloning gene fragments into 
Rhodococcus erythropolis CW25, a bacterium unable to 
metabolize cocaine but able to grow on the cocaine esterase 
byproducts ecgonine methyl ester and benzoate (Bresler eta!. 
(2000) Applied & Environmental Microbiology 66, 
904-908). The CocE gene has been subcloned into shuttle 
vectors pJAK-14 and pMMB67EH (see e.g., Example 1). 
These plasmids are capable of expression in any gram-nega-
tive bacterium including Pseudomonas, and additionally the 
pMMB67EH plasmid enables high levels of expression and 
ease of transformation by bacterial conjugation with the use 
of helper plasmid pRK2013. Transformation of either plas-
mid into bacteria that exhibit temperature sensitive growth on 
cocaine esterase byproducts (e.g., Pseudomonas strains), 
enables temperature sensitive growth on plates containing 
cocaine as a sole source of carbon. Mutagenesis of both the 
original Rhodococcus MB1 and the CocE plasmid-contain-
ing Pseudomonas strains is performed using UV-light radia-
tion at 260 nm. Exposure is titrated such that 90-95% of cells 
are killed. The remaining cells are recovered in nutrient media 
for 1 hr at 26° C., collected and enriched in the presence of 
cocaine as previously described (Britt, eta!. (1992) Journal of 
Bacteriology 174, 2087-2094). Enrichment is performed at 
3 7° C. to select for thermostable variants of the CocE. Finally, 
cells are plated onto minimal media agar plates containing 10 
mM cocaine and incubated at 37° C. Single colonies are 
grown and tested for CocE activity at 37° C. PCR amplifica-
tested for esterase activity at temperatures 30° C. and above. 
After several rounds of mutagenesis and testing at increasing 
temperatures thermostable mutants are achieved. Each indi-
25 vidual mutant CocE is then prepared, purified, and tested for 
activity and thermo stability at 37° C., as described above (see 
Examples 1 and 4) 
Bacterial colonies containing mutant polypeptides are 
screened from directly from agar plates by nitrocellulose 
30 filter imprint of replica plates followed by lysis of the bacteria 
and protein fixation. Determination of enzymatic activity at 
various temperatures is achieved by monitoring the accumu-
lation of benzoic acid, the acidic by product of (-)cocaine. A 
moist nitrocellulose imprint is placed onto a dried filter paper 
35 previously saturated with a mixture of cocaine at pH 7.4 with 
no buffer and a pH indicator that transitions from colorless to 
color upon acidification e.g., methyl red. Active enzyme is 
identified by color change and colonies are appropriately 
harvested. The detection method based on acidification 
40 through the formation of benzoic acid is employed for the 
detection of cell expression of catalytic antibodies that hydro-
lyze cocaine at the benzoyl ester group, the same site cleaved 
by CocE. Alternatively, detection by nitrocellulose imprint is 
achieved by exposure to a cocaine thiol-derivative and sub-
45 sequent detection of sulfhydryl groups via a precipitating 
heavy-metal (e.g., mercury-based) indicator system. 
Bacterial colonies containing mutant polypeptides are also 
screened by subculturing into liquid medium and testing 
directly for cocaine esterase activity using a cocaine thiol-
50 derivative and detection using the colorimetric thiol indicator, 
Ellman's reagent (see e.g., FIG. 6). Ellman's reagent rapidly 
forms a disulfide bond with free thiol-groups and releases a 
colored thiolate ion which absorbs at 412 nm. Cultures incu-
bated overnight at 16° C. in the presence of IPTG to induce 
55 protein expression (20 I) are mixed with 1 mM benzoylth-
ioester cocaine derivative, and 500 uM Ellman's reagent in 
100 mM sodium phosphate pH 7.4 to a final volume of 200 I. 
Results (see e.g., FIG. 6) indicate that cells containing the 
wild-type CocE enzyme are able to cleave the benzoylth-
60 ioester at much higher levels than cells alone. 
Finally bacterial colonies containing mutant polypeptides 
are screened by subculturing into liquid medium followed by 
lysis and isolation of mutant polypeptides using an affinity 
medium. For example, lysed cells are washed through nickel-
65 agarose filter-plates allowing collection and subsequent elu-
tion of 6xHIS tagged proteins (for example, Ni-NTA Super-
flow 96-Bio-robot kit (Qiagen). Alternatively, cells are lysed 
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within nickel-coated microtiter plates allowing binding of 
6xHIS fusion proteins and subsequent removal of contami-
nants (for example, immobilizer nickel chelate plates (Nunc) 
or NEN Nickel-chelate flash plates (Perkin Elmer)). Simi-
larly, lysed cells are incubated with nickel coated micro beads 
(such as Ni-NTAmagnetic agarose beads (Qiagen)), followed 
by subsequent removal of contaminating proteins. Isolated 
esterase protein activity are then tested using any of the assays 
previously mentioned (such as the spectrophotometric activ-
ity assay (Examples 1 and 4), the tritiated cocaine activity 10 
assay (Example 1 ), the benzoic acid pH indication activity 
assay, the thiol-derivative cocaine detection systems, the use 
of cocaine aptamers (Stojanovic, M. N., de Prada, P. & Lan-
dry, D. W. (2001) JAm Chern Soc 123, 4928-31; Stojanovic, 15 
M. N. & Landry, D. W. (2002) JAm Chern Soc 124, 9678-9) 
by monitoring changes in fluorescence upon degradation of 
cocaine, or by the use of a generic esterase substrate such as 
4-nitrophenyl acetate and monitoring of colorimetric changes 
at420 nmas described previously (Halgasova, N. eta!. (1994) 20 
Biochem J 298 Pt 3, 751-5; O'Conner, C. J. & Manuel, R. D. 
(1993) J Dairy Sci. 76:3674-3682). 
Example 16 
Preliminary Analysis ofN197K Mutant Polypeptide 
Preliminary analysis of the N197K mutant polypeptide 
(SEQ ID NO: 42) showed good stability after 1 hour at 37° C. 
25 
on day 0. Vmax and Km values are shown in Table 5. A 
30 
recheck on day 3 showed similar stability. Vmax and Km 
values are shown in Table 6. Higher Km values on day 3 were 
due to reuse of old cocaine. Gel filtration of samples incu-
bated at 37° C. showed formation of aggregates. 
Equation 1 
Best-fit values 
VMAX 
KM 
Equation 1 
Best-fit values 
VMAX 
KM 
TABLES 
N197K initial test (Day 0) 
N197K(O) 
2928 
34.77 
TABLE6 
N197K repeat test (Day 3) 
N197K(O) 
3357 
102.2 
N197K (60) 
2187 
24.24 
N197K (60) 
3085 
113.5 
35 
40 
45 
50 
44 
various embodiments, the combination of two single muta-
tions with lower or no stability can result in a thermally stable 
combination. 
TABLE 7 
Thermally stable mutant CocE polypeptides 
Mutant 
T122A 
Q123E 
S159A 
S140A 
S167AIW52L 
T172R 
V121D 
L163V 
F189A 
F189A/T172R 
C107S 
W220A 
F189L 
A193D 
T172R/A193D 
G173Q 
T254R 
N42V 
T172R/G 173Q 
G 171 Q/T172R/G 173Q 
G171A 
G173A 
wt-1175-G-D185 
wt-T17 6-G-G-D185 
T172R/G173Q-1175-G-D185 
T172R/G173Q-1175-G-G-
A186 
T172R/G 173Q-T176-G-G-
D185 
S177Q 
D45R 
F47R 
L169K 
L174R 
A181K 
S179R 
F189K 
V190K 
A194K 
R182K 
Example 18 
Stability@ 37° C. (t112) 
No 
No 
No 
No 
No 
-46min 
No 
No 
No 
-40 min (Similar to 
T172R) 
No 
No 
No 
No 
-40 min (Similar to 
T172R) 
-25 min 
No 
No 
-326min 
No 
No 
No 
No 
No 
-75 min 
-75 min 
No 
No 
No 
-274min 
No 
No 
No 
25 min 
No 
No 
No 
Protection of Aggregation of Thermal Stable 
Cocaine Esterase Mutants 
Protection from aggregation of thermal stable CocE 
mutants was assessed using size exclusion chromatography. 
Briefly, enzymes were preincubated at 3 7° C. for 0 minutes or 
60 minutes and resolved by size exclusion chromatography. 
Example 17 55 Results for wild-type CocE, T172R and T172R/G 173Q are 
shown in FIG. 28. 
Identification of Thermally Stable Mutant CocE 
Polypeptides 
Thermally stable mutant CocE polypeptides were identi- 60 
fied by determining 112 of the mutant CocE polypeptides. 
Briefly, enzymes were preincubated at 37° C. for varying 
times. Activity measurements were determined at RT (25° 
C.). Mutant enzymes with 112 of greater than 12 minutes 
(the 112 of wild type CocE) were considered thermally stable 65 
(See, e.g., FIG. 27 and Table 7). As demonstrated by the 
combination mutant CocE polypeptide T172R/G 173Q, in 
Example 19 
Low-UV Spectra 
Low-UV CD spectra data were obtained using an Aviv 
Spectropolarimeter Mode 400, with the help of Norma 
Greenfield, UMDNJ, using a 5-cell holder and 0.2 mg/ml 
protein concentrations. Raw data values obtained were 
blanked on control PBS, smoothed, and deconvoluted using 
the CCA algorithm as described by A. Perczel, K. Park, and 
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G. D. Fasman, [Analysis of the circular dichroism spectrum 
of proteins using the convex constraint algorithm: a practical 
guide. Analytical Biochemistry 203, 83-93 (1992).] This 
algorithm finds the minimum number of curves needed to 
reconstruct a data set, and expresses the percentage each 
curve contributes to the data set as a function of temperature. 
Below is presented a low UV CCA denconvolution analy-
sis of CocE WT and 4 mutants, obtained in a single CD 
spectra melt using a 5-cell holder. The experiment was per- 10 
formed over the period of 8 hours, from 0-80° C. 
Temperature dependent melting was observed between the 
wavelengths tested (200-250 nm), and the smoothed spectra 
for each mutant are shown in FIG. 29. Deconvolution via the 
CCA algorithm indicated that each spectra was best described 15 
by a set of three curves, as shown in FIG. 30. This suggests 
that the melting ofCocE is at least a two step process, moving 
from an original curve (curve 1) to an intermediate unfolding 
step (curve 2), and finally fully denatured protein (curve 3). 
20 The % contribution that each temperature played in describ-
ing these three curves is shown in FIG. 31. Dose response 
analysis was used to approximate the temperature at which 
the initial spectra melts (1 ), the formation and melt of the 
intermediate state (2), and the accumulation of the fully 25 
melted protein (3 ). These numbers were collected and plotted 
in FIG. 32 and shown in Table 8. 
TABLES 
30 
Melting points of each step 
#1 melt #2 formation #2melt #3 formation 
---wT 37.04 34.57 50.98 59.86 
----~---- T172R 39.22 38.11 54.56 56.85 
T172R-A193D 38.11 46.47 47.68 58.72 35 
T172R-F189K 38.8 46.81 48.42 57.23 
---><-- T172R-G 173Q 40.62 45.61 46.17 56.61 
46 
Example 20 
Stabilization Using Products and Inhibitors 
Cocaine esterase (CocE) cleaves cocaine to produce Ben-
zoic acid and Ecgonine methyl ester. Briefly, alternative sub-
strates and inhibitors of cocaine, as well as compounds able to 
thermostabilize the enzyme, were investigated generally by 
substituting amide and thiol analogues at the reactive ester 
bond, or removing the bond (for inhibitors), substituting ben-
zoyl analogues in place of the benzoic acid leaving group, 
and/or removing or altering the methyl-ester group on the 
ecgonine portion of the molecule. As discussed below, it was 
determined that some substrates, products, and inhibitors sta-
bilized thermal denaturation of wild type CocE, as well as 
prevented thermally-induced aggregation in gel electro-
phoresis. 
Cocaine is the natural substrate of Cocaine esterase 
(CocE). Cocaine cleavage was monitored by a drop in absor-
bance at 240 nm. Cocaine (mM range) prevented 37° C.-in-
duced formation of high molecular weight CocE aggregates 
(0.1 mg/ml enzyme concentrations) (see, e.g., FIG. 33). 
Cocaine (uM quantities) stabilized 37° C.-induced activity 
loss (see, e.g., FIG. 34), although the mechanism of this 
stabilization is complicated due to substrate inhibition at 
higher concentrations. 
Benzoic acid is the natural product of CocE and a weak 
inhibitor ofCocE cleavage of 4-nitrophenyl acetate (Ki 310 
uM). Benzoic acid prevented 37° C.-induced formation of 
high molecular weight CocE aggregates (0.1 mg/ml enzyme 
concentrations) (see, e.g., FIG. 35). Benzoic acid (uM quan-
tities) stabilized 37° C.-induced activity loss (see, e.g., FIG. 
36), although the mechanism of this stabilization is compli-
cated due to substrate inhibition at higher concentrations. 
CocE catalyzes the cleavage of 4-nitrophenyl acetate 
(4NPA) to 4-nitrophenol (4NP) and acetate. The cleavage 
reaction was monitored by observation of product formation 
at 400 nm. Both 4NP and 4NPA (mM range) prevented 37° 
C.-induced formation of high molecular weight CocE aggre-
gates (0.1 mg/ml enzyme concentrations). 
The most thermostable mutant T172R -G 173Q (as deter-
mined in other assays) showed the highest temperature melt-
ing of the original curve 1 (40° C. vs 37° C. for wild-type), and 
the lowest temperature for both disappearance of the curve 2 
intermediate ( 46° C. vs 50° C. for wild-type) and appearance 
of the fully melted curve 3 (56° C. vs 59° C. for wild-type). 
Phenylboronic acid is a potent inhibitor of CocE (Ki 250 
40 nM). Phenylboronic acid stabilized 37° C.-induced aggrega-
tion of CocE with an EC50 of 0.2 UM by densitometry 
analysis. 
In summary, it appears that all mutants undergo a 2-step 
melting process. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 47 
<210> SEQ ID NO 1 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Rhodococcus sp. MB1 
<400> SEQUENCE, 1 
Using the above, a screening assay is developed to screen 
for small molecules that might similarly stabilize the enzyme 
45 but not necessarily occupy the active site. Molecules identi-
fied as stabilizing molecules are used to stabilize the proteins 
disclosed herein until ready for use. 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
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-continued 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
48 
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-continued 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 2 
<211> LENGTH, 2692 
<212> TYPE, DNA 
<213> ORGANISM, Rhodococcus sp. MB1 
<400> SEQUENCE, 2 
gatccagcga aggtcgggag tgaatggtgg acgggaatta cagtgttgcc tcgaacgtga 
tggttccgat gcgtgatggg gtgcgtctgg cggtcgacct gtaccgacca gatgctgatg 
gacctgttcc ggtcctgctg gttcgcaacc catacgacaa gttcgacgtg ttcgcgtggt 
cgacgcagtc gacaaactgg cttgagttcg tgcgtgatgg ctatgccgtg gtcattcaag 
acacgcgtgg cttgttcgca tcggaaggtg agttcgtccc gcacgttgac gacgaagctg 
acgccgagga tacgttgagc tggattctgg aacaagcgtg gtgcgacggc aatgtgggca 
tgttcggcgt ttcgtacttg ggtgtgaccc agtggcaggc cgccgtatcc ggcgttggtg 
ggctgaaggc gatcgcgccg tccatggcgt cggcggactt gtaccgcgcc ccgtggtacg 
gccctggtgg tgcgctttca gtcgaggcgc tgttgggctg gtcagctctc ataggtactg 
ggctcatcac gtcgaggtct gacgcccggc ccgaagacgc agccgacttc gtccaactcg 
cagcaattct caatgacgtc gctggcgcgg cgtcggtcac gcccctggcc gagcaaccgc 
ttctgggccg actgattccg tgggtgatcg atcaggttgt cgatcacccc gacaacgatg 
aatcatggca gtccattagc ttgtttgaac gactcggcgg gttggcaaca ccggccttga 
tcacggctgg gtggtacgac gggttcgtcg gcgaatcgtt gcgcactttc gttgcggtca 
aggacaatgc cgacgcacgt ttggttgtcg gcccttggag tcacagcaac ctcactggtc 
ggaatgcgga ccggaagttc ggcattgccg cgacctaccc gattcaagaa gccaccacga 
tgcacaaggc attcttcgac cggcacctcc gcggcgagac cgatgcactc gcaggcgtcc 
ccaaagtgcg gctgttcgta atgggcatcg atgagtggcg tgacgaaacg gactggccac 
tgccggacac ggcgtatacg cccttctatc ttggaggtag cggggctgcg aatacctcca 
cgggtggtgg aacactgtcg acgtcgattt ccggaactga atctgctgac acctacctgt 
atgatccggc cgatcccgtg ccttcgctcg gggggacgct gctgttccac aacggagaca 
acggacccgc cgaccaacgt cccattcatg accgggacga cgtgttgtgt tacagcactg 
aggtattgac cgacccggtg gaagtaaccg gcaccgtctc cgcccggctg ttcgtgtcgt 
catcagcggt ggacactgat ttcaccgcca aacttgtcga cgtatttccc gacggtcgcg 
cgatcgcgct gtgtgacggg atcgtgcgga tgcggtaccg cgagacgttg gtcaatccaa 
ccttgatcga agcgggcgaa atctacgagg ttgctatcga catgcttgca acctcgaatg 
50 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
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51 
-continued 
tattcctgcc agggcatcgc atcatggtcc aagtatcaag tagcaacttc ccgaaatacg 
accgcaattc gaataccggc ggagtaatcg cacgggaaca gctcgaagag atgtgcaccg 
ccgtgaaccg cattcaccga ggacctgagc atcccagcca cattgtgctg ccgattatca 
agcgatagtt ttcggtgcag ccgcgcctgg ctgacgctgc agctcaaacc caatggctcg 
gcaaccggta cgcgctcgcc gccctgcact ttccaccatg cgtaggtcgt cagcggccga 
ctgaaggccg gattgcatcc cgacccggcg accctaggtc aggcgaattg tccgaatgtc 
agcggtcatg taattcccca ggttgagcgg ttcgtcggtc acgtaattcc tcaccctgcc 
gtcacgtagt tccccaccct gggcgtgtcg gtcggggtgc gggtgctgct gcaggttcgc 
cccctcccaa ggtccacctg gggaaggggc ccgacggtgg caaggagaac gtggacgatg 
accgatctga cgatgaccga tctgatggag ttcttccggc actggcatgc cgggcgttcg 
caggttcaga tctcaccggc gtttgggatc gaccgcaaaa cctgacttgc acaagttgac 
ggcggtttcc ggactcggct gacatttgcg caagtagaag gccccgcggg ttcgggattt 
ggcgcactaa cgggtcggta aaatctggcg agtggcggcg tacattcgca aggtcaggac 
cgcatcgggg gcgaccgcgg tgcagatcgc cgtcaagcag ggacgtcgcg acaaggtgcg 
tcgagcacct cggttccgca cacaccgaca gcgagcttgc tgcgctactg caggccgccg 
aggagaagct gcaggtcgga cagtaggaac tcgacctcga cctcggcggt agcggggatc 
gagggtcggt gatcgcggcg aagcggtccc gctggttgat cgaggcgatc gagaccggat 
gacggcggct cggcttcgac gtgatcgacg acgaggtgtt catctaactg gtgatcggca 
ggctcgtcga accgacctcg atgagcgaca ccggccggga atcgccgaga tc 
<210> SEQ ID NO 3 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 3 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
52 
1620 
1680 
1740 
1800 
1860 
1920 
1980 
2040 
2100 
2160 
2220 
2280 
2340 
2400 
2460 
2520 
2580 
2640 
2692 
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53 
-continued 
Glu Ala Val Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
54 
<210> SEQ ID NO 4 
<211> LENGTH, 574 
<212> TYPE, PRT 
55 
<213> ORGANISM, Artificial 
<220> FEATURE, 
US 9,200,265 B2 
-continued 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 4 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Asp Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
56 
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57 
-continued 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 5 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 5 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ala Ala Leu Ile Gly Thr Gly Leu Ile Thr 
58 
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59 
-continued 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 6 
60 
<211> LENGTH, 574 
<212> TYPE, PRT 
61 
<213> ORGANISM, Artificial 
<220> FEATURE, 
US 9,200,265 B2 
-continued 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Glu Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
62 
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63 
-continued 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 7 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 7 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
64 
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65 
-continued 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Ile Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 8 
<211> LENGTH, 574 
570 
66 
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67 
-continued 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 8 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Leu Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
68 
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69 
-continued 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 9 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 9 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
70 
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71 
-continued 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Asp Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 10 
<211> LENGTH, 574 
<212> TYPE, PRT 
570 
72 
73 
<213> ORGANISM, Artificial 
<220> FEATURE, 
US 9,200,265 B2 
-continued 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 10 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ser Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
74 
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75 
-continued 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 11 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 11 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ala Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
76 
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77 
-continued 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 12 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
570 
78 
US 9,200,265 B2 
79 
-continued 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 12 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ala Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
80 
US 9,200,265 B2 
81 
-continued 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 13 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 13 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Gly Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
82 
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83 
-continued 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 14 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
84 
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85 
-continued 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 14 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Ala Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
86 
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87 
-continued 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 15 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 15 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Ala Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
88 
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89 
-continued 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 16 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
90 
US 9,200,265 B2 
91 
-continued 
<400> SEQUENCE, 16 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ala Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
92 
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-continued 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 17 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 17 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Leu Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
94 
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95 
-continued 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 18 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
96 
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-continued 
<400> SEQUENCE, 18 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Asp Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
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-continued 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 19 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 19 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
100 
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101 
-continued 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Arg Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 20 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 20 
102 
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103 
-continued 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Val Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
104 
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-continued 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 21 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 21 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
106 
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-continued 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Leu Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 22 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 22 
108 
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-continued 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
110 
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111 
-continued 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Gly Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val 
545 550 
Pro Glu His Pro Ser His Ile Val Leu Pro 
565 
<210> SEQ ID NO 23 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
540 
Asn Arg Ile His Arg 
555 
Ile Ile Lys Arg 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 23 
Gly 
560 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp His Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
112 
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113 
-continued 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 24 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 24 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
114 
US 9,200,265 B2 
115 
-continued 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Ala 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
116 
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117 
-continued 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val 
545 550 
Pro Glu His Pro Ser His Ile Val Leu Pro 
565 
<210> SEQ ID NO 25 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
540 
Asn Arg Ile His Arg 
555 
Ile Ile Lys Arg 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 25 
Gly 
560 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Arg Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
118 
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119 
-continued 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val 
545 550 
Pro Glu His Pro Ser His Ile Val Leu Pro 
565 
<210> SEQ ID NO 26 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
540 
Asn Arg Ile His Arg 
555 
Ile Ile Lys Arg 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 26 
Gly 
560 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
120 
US 9,200,265 B2 
121 
-continued 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
122 
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123 
-continued 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Phe Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 27 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 27 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Ser Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
124 
US 9,200,265 B2 
125 
-continued 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val 
545 550 
Pro Glu His Pro Ser His Ile Val Leu Pro 
565 
<210> SEQ ID NO 28 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
540 
Asn Arg Ile His Arg 
555 
Ile Ile Lys Arg 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 28 
Gly 
560 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
126 
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127 
-continued 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Thr Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
128 
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129 
-continued 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 29 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 29 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Pro Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
130 
US 9,200,265 B2 
131 
-continued 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 30 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 30 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
132 
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133 
-continued 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
134 
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135 
-continued 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Ser Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val 
545 550 
Pro Glu His Pro Ser His Ile Val Leu Pro 
565 
<210> SEQ ID NO 31 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
540 
Asn Arg Ile His Arg 
555 
Ile Ile Lys Arg 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 31 
Gly 
560 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Arg Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
136 
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137 
-continued 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 32 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 32 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
138 
US 9,200,265 B2 
139 
-continued 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gln Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
140 
US 9,200,265 B2 
141 
-continued 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val 
545 550 
Pro Glu His Pro Ser His Ile Val Leu Pro 
565 
<210> SEQ ID NO 33 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
540 
Asn Arg Ile His Arg 
555 
Ile Ile Lys Arg 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 33 
Gly 
560 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
142 
US 9,200,265 B2 
143 
-continued 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Thr Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 34 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 34 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
144 
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145 
-continued 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
146 
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147 
-continued 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Ala Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 35 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, R41I 
<400> SEQUENCE, 35 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Ile Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
148 
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149 
-continued 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 36 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 36 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
150 
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151 
-continued 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Ala Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
152 
US 9,200,265 B2 
153 
-continued 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 37 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 37 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Ala Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
154 
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155 
-continued 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
<210> SEQ ID NO 38 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 38 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
156 
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157 
-continued 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Tyr Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
158 
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159 
-continued 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val 
545 550 
Pro Glu His Pro Ser His Ile Val Leu Pro 
565 
<210> SEQ ID NO 39 
<211> LENGTH, 587 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
540 
Asn Arg Ile His Arg 
555 
Ile Ile Lys Arg 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 39 
Gly 
560 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Arg Gln Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
160 
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161 
-continued 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg Lys Leu 
565 570 575 
Ala Ala Ala Leu Glu His His His His His His 
580 
<210> SEQ ID NO 40 
<211> LENGTH, 587 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
585 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 40 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
162 
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163 
-continued 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Arg Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
164 
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165 
-continued 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg Lys Leu 
565 570 575 
Ala Ala Ala Leu Glu His His His His His His 
580 585 
<210> SEQ ID NO 41 
<211> LENGTH, 587 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 41 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Arg Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Ala Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
166 
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167 
-continued 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg Lys Leu 
565 570 575 
Ala Ala Ala Leu Glu His His His His His His 
580 
<210> SEQ ID NO 42 
<211> LENGTH, 582 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
585 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 42 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
168 
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169 
-continued 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Lys Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
170 
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-continued 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val 
545 550 
Pro Glu His Pro Ser His Ile Val Leu Pro 
565 
His His His His His His 
580 
<210> SEQ ID NO 43 
<211> LENGTH, 582 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
540 
Asn Arg Ile His Arg 
555 
Ile Ile Lys Arg Leu 
575 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 43 
Gly 
560 
Glu 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Lys Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
172 
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-continued 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg Leu Glu 
565 
His His His His His His 
580 
<210> SEQ ID NO 44 
<211> LENGTH, 582 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 575 
174 
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175 
-continued 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 44 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Lys Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
176 
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177 
-continued 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg Leu Glu 
565 570 575 
His His His His His His 
580 
<210> SEQ ID NO 45 
<211> LENGTH, 582 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 45 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
178 
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-continued 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Lys Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg Leu Glu 
565 
His His His His His His 
580 
570 575 
180 
<210> SEQ ID NO 46 
<211> LENGTH, 582 
<212> TYPE, PRT 
181 
<213> ORGANISM, Artificial 
<220> FEATURE, 
US 9,200,265 B2 
-continued 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 46 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Lys Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Gln Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
182 
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183 
-continued 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg Leu Glu 
565 570 575 
His His His His His His 
580 
<210> SEQ ID NO 47 
<211> LENGTH, 582 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutant CocE polypeptide 
<400> SEQUENCE, 47 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
184 
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185 
-continued 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Lys Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
186 
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-continued 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg Leu Glu 
565 570 575 
His His His His His His 
580 
The invention claimed is: 
1. An isolated mutant cocaine esterase (CocE) polypeptide 
comprising 
an amino acid sequence at least 90% identical to SEQ ID 15 
NO: 1, having at least one substitution, addition or dele-
tion, 
wherein 
the at least one substitution, addition or deletion is 
selected from the group consisting ofL163V; V225I; 20 
I218L; A310D; A149S; S159A; S265A; S56G; 
W220A; S140A; F189L; A193D; T254R; N42V; 
V262L; L508G; Y152H; V160A; T172R; Y532F; 
T74S; W285T; L146P; D533S; A194R; G173Q; 
C477T; K531A; R41I; L119A; K46A; F84Y; T172R- 25 
G173Q; L169K; F189A; N197K; R182K; F189K; 
V190K; Q191K; A194K; I175-G-G-A186; and 
T176-G-G-Dl85; and 
the mutant CocE polypeptide has esterase activity. 
2. The mutant CocE polypeptide of claim 1, wherein the 
30 
mutant CocE polypeptide comprises increased thermostabil-
ity at 3 7° C. as compared to wild-type CocE having the amino 
acid sequence of SEQ ID NO: 1. 
3. The mutant CocE polypeptide of claim 2, wherein the 
increase in thermostability of the mutant CocE polypeptide 
35 
over wild-type CocE having the amino acid sequence of SEQ 
ID N0:1 is about 2.1 kcal/mol or greater. 
4. The mutant CocE polypeptide of claim 1, wherein at 
least two amino acid residues are substituted. 
5. The mutant CocE polypeptide of claim 1, wherein at 
40 
least three amino acid residues are substituted. 
6. The mutant CocE polypeptide of claim 1, wherein at 
least four amino acid residues are substituted. 
7. The mutant CocE polypeptide of claim 1, wherein at 
least five amino acid residues are substituted. 
45 
8. The mutant CocE polypeptide of claim 1, comprising an 
amino acid sequence selected from the group consisting of 
SEQIDNO: 3 (L163V); SEQIDNO: 7(V225I); SEQIDNO: 
8 (I218L); SEQIDNO: 9 (A310D); SEQIDNO: 10(A149S); 
SEQ ID NO: 11 (S159A); SEQ ID NO: 12 (S265A); SEQ ID 50 
NO: 13 (S56G); SEQ ID NO: 14(W220A); SEQ ID NO: 16 
(S140A); SEQ ID NO: 17 (F189L); SEQ ID NO: 18 
(A193D); SEQ ID NO: 19 (T254R); SEQ ID NO: 20 (N42V); 
SEQ ID NO: 21 (V262L); SEQ ID NO: 22 (L508G); SEQ ID 
NO: 23 (Y152H); SEQ ID NO: 24 (V160A); SEQ ID NO: 
25(T172R); SEQ ID NO: 26 (Y532F); SEQ ID NO: 27 
(T74S); SEQ ID NO: 28 (W285T); SEQ ID NO: 29 (L146P); 
SEQ ID NO: 30 (D533S); SEQ ID NO: 31 (A194R); SEQ ID 
NO: 32 (G173Q); SEQ ID NO: 33 (C477T); SEQ ID NO: 34 
(K531A); SEQ ID NO: 35(R41I); SEQ ID NO: 36 (L119A); 
SEQ ID NO: 37 (K46A); SEQ ID NO: 38 (F84Y), SEQ ID 
NO: 39 (T172R-G173Q); SEQ ID NO: 40 (L169K); SEQ ID 
NO: 41 (F189A), SEQ ID NO: 42 (N197K), SEQ ID NO: 43 
(R182K), SEQ ID NO: 44 (F189K), SEQ ID NO: 
45(V190K), SEQ ID NO: 46 (Q191K), and SEQ ID NO: 47 
(A194K). 
9. The mutant CocE polypeptide of claim 1, encoded by a 
nucleic acid having at least 90% sequence identity with SEQ 
IDNO: 2. 
10. The mutant CocE polypeptide of claim 9, comprising a 
substitution, addition or deletion of F189A/T172R· T172R/ 
A193D; T172R/G 173Q; T172R/G 173Q-I175-G-G-A186; or 
T172R/G173Q-T176-G-G-Dl85. 
11. The polypeptide of claim 1, wherein the mutant CocE 
polypeptide has at least or about 10% of the esterase activity 
of wild-type CocE polypeptide. 
12. The mutant CocE polypeptide of claim 1, wherein the 
mutant CocE polypeptide is pegylated. 
13. The mutant CocE polypeptide of claim 1, stabilized by 
a substrate or inhibitor. 
14. The mutant CocE polypeptide of claim 1, comprising a 
substitution, addition or deletion ofT172R; F189A; A193D; 
G173Q; G173Q-I175-G-G-A186; G173Q-T176-G-G-Dl85; 
L169K; or F189K. 
15. A pharmaceutical composition comprising the mutant 
CocE polypeptide of claim 1 and a pharmaceutically accept-
able carrier or excipient. 
16. The pharmaceutical composition of claim 15, suitable 
for parenteral administration. 
17. The pharmaceutical composition of claim 15, wherein 
the mutant CocE polypeptide comprises a lyophilized mutant 
CocE polypeptide. 
18. The pharmaceutical composition of claim 15, wherein 
the pharmaceutical composition is a lyophilized pharmaceu-
tical composition. 
19. The mutant CocE polypeptide of claim 1, comprising 
substitutions ofT172R and G173Q. 
* * * * * 
